Common Variable Immunodeficiency

On this page

Quick Reference

RxDrug of choiceImmunoglobulin replacement therapy (IVIG 400-600 mg/kg q3-4wk or SCIG 100-200 mg/kg weekly) titrated to individual trough.

AltAlternativesAntimicrobial prophylaxis (TMP-SMX DS daily or azithromycin 250 mg TIW); for non-infectious complications: prednisone ≥0.3 mg/kg/day, rituximab 150-375 mg/m², abatacept (CTLA-4 insufficiency), sirolimus (LRBA deficiency), omalizumab (CSU), PD-1 inhibitors (malignancy).

⊘AvoidLive vaccines; IgA-containing IVIG in patients with anti-IgA antibodies; non-dihydropyridine CCBs (diltiazem, verapamil) in CVID with cardiac involvement.

DxTest of choiceSerum immunoglobulins (IgG, IgA, IgM, IgE) plus vaccine response testing (pneumococcal polysaccharide + protein antigens) plus B-cell immunophenotyping (switched memory B cells, CD21low B cells).

ScKey scoreEUROclass classification (smB <2% = high risk; CD21low >10% = lymphoproliferation) and clinical phenotype (infection-only vs complicated CVID).

→When to referRefer to immunology at diagnosis; consider specialized center for complicated CVID (non-infectious complications, monogenic defect, refractory disease, need for HSCT or targeted biologic).

CVID is the most common primary immunodeficiency in adults, driven by humoral and T-cell defects. Early immunoglobulin replacement reduces infections, but non-infectious complications (autoimmune cytopenias, lymphoproliferation, GLILD, malignancy) determine prognosis and require targeted immunosuppression. Monogenic causes guide therapy, and systematic surveillance improves outcomes.

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, characterized by low serum immunoglobulins (IgG and IgA and/or IgM) and impaired specific antibody responses. The disease manifests with recurrent sinopulmonary infections, autoimmune cytopenias, lymphoproliferation, enteropathy, and increased malignancy risk, complications that now dominate morbidity and mortality. Diagnostic delays of 5-8 years are common. Early immunoglobulin replacement therapy reduces infection frequency and improves survival; effective management requires parallel strategies for infectious prophylaxis and targeted immunosuppression for non-infectious complications. This overview synthesizes the current paradigm for evaluation and management.

Overview and Recommendations

Background

•CVID is the most common symptomatic primary immunodeficiency in adults, with an estimated prevalence of 1 in 500 to 1 in 500,000. It is defined by low serum IgG and low IgA (with or without low IgM) and defective specific antibody production, leading to recurrent infections and immune dysregulation that spans B- and T-cell compartments.
•The classic presentation involves recurrent sinopulmonary infections (pneumonia as first manifestation in 32% of patients), but non-infectious complications, autoimmune cytopenias (ITP, AIHA, Evans syndrome), lymphoproliferation (splenomegaly, lymphadenopathy), enteropathy, granulomatous-lymphocytic interstitial lung disease (GLILD), and malignancy, now drive most morbidity. The presence of even one non-infectious complication confers an 11-fold increase in mortality compared with infection-only disease.
•Pathophysiology centers on a fundamental B-cell maturational defect (reduced class-switched memory B cells) compounded by T-cell dysregulation: follicular helper T-cell expansion, regulatory T-cell deficiency, and chronic innate immune activation driven by microbial translocation. IgA deficiency with impaired anti-LPS antibodies permits endotoxemia, which triggers a BTK-dependent proinflammatory cytokine cascade (TNF-α, IL-6, IFN-γ, CXCL9, CXCL10) in genetically susceptible individuals.
•Monogenic causes are identified in 20-30% of patients, most commonly heterozygous loss-of-function variants in (4% of Europeans), haploinsufficiency, deficiency, and defects in , , , and . Identification of a specific genetic defect can guide targeted therapy (e.g., abatacept for CTLA-4 insufficiency, sirolimus for LRBA deficiency) and consideration of hematopoietic stem cell transplantation.
•Diagnostic criteria per ESID/ICON require onset after age 2 years, low IgG and low IgA (and/or low IgM), impaired vaccine responses to pneumococcal polysaccharide and protein antigens, and exclusion of secondary causes of hypogammaglobulinemia. Patients are clinically stratified into infection-only (CVIDio) and complicated CVID (CVIDc), the latter encompassing autoimmune, lymphoproliferative, enteropathic, and malignant phenotypes, to guide prognosis and surveillance intensity.

Evaluation

•Suspect CVID in any adult with recurrent sinopulmonary infections (≥2 pneumonias in 1 year, chronic sinusitis, otitis media), especially when accompanied by unexplained autoimmune cytopenia, splenomegaly, lymphadenopathy, chronic diarrhea, or bronchiectasis.
•Ask about age at first serious infection, frequency of antibiotic courses, history of pneumonia, bronchiectasis, autoimmune disease (ITP, AIHA, Evans syndrome), family history of immunodeficiency, and prior immunoglobulin measurements. Diagnostic delay averages 5-8 years, so maintain a low threshold.
•Examine for signs of chronic lung disease (crackles, clubbing), lymphadenopathy, splenomegaly, mucocutaneous candidiasis, and skin findings (vitiligo in 8.5%, eczema in 22.4%, purpura from thrombocytopenia).
•Order initial laboratory workup: complete blood count with differential, serum immunoglobulins (IgG, IgA, IgM, IgE), and serum protein electrophoresis with calculated globulin (CG <22 g/L has 80% sensitivity, 87% specificity for hypogammaglobulinemia). Low IgG and low IgA are required for diagnosis.
•Evaluate specific antibody responses by measuring pre- and 4-week post-vaccination titers to pneumococcal polysaccharide (Pneumovax) and protein antigens (tetanus, diphtheria). Failure to achieve a ≥2-fold rise or protective levels in <70% of serotypes defines the defect. If the patient is already on IVIG, use ELISPOT assay for antibody-secreting cells instead of serology.
•Perform B-cell immunophenotyping by flow cytometry: quantify switched memory B cells (CD27+IgD-), marked reduction (<2% of B cells) is a hallmark of CVID and predicts non-infectious complications. Expansion of CD21low B cells (>5% of B cells) correlates with GLILD and splenomegaly.
•Assess T-cell subsets: low naive CD4+ T cells (<20% of total CD4+) defines late-onset combined immunodeficiency (LOCID), which independently predicts splenomegaly, lymphadenopathy, interstitial lung disease, lymphoma, and shortened survival.
•Consider serum B-cell maturation antigen (sBCMA) as a novel biomarker: <15 ng/mL has 97% positive predictive value for CVID or X-linked agammaglobulinemia; ≥25 ng/mL has 88% negative predictive value.
•Genetic testing (targeted gene panel or whole exome) is indicated for patients with non-infectious complications dominating the phenotype, family history of immunodeficiency, or severe/atypical infections. Identification of a monogenic cause (NFKB1, CTLA4, LRBA, etc.) can direct targeted therapy and cascade screening of relatives.
•In patients with atopic symptoms but negative skin prick testing or serum specific IgE, consider bronchial challenge to confirm allergic asthma, as standard allergy testing is often falsely negative in CVID (only 9.7% have atopy by skin test despite suggestive histories).
•Rule out secondary causes of hypogammaglobulinemia: medications (rituximab, anticonvulsants, sulfasalazine), protein-losing enteropathy, nephrotic syndrome, lymphoproliferative diseases (CLL, thymoma/Good syndrome), and chronic infections (HIV, EBV, CMV).
•Perform baseline screening for established complications: high-resolution chest CT (HRCT) to assess for bronchiectasis and GLILD, pulmonary function tests including FVC and DLCO, and upper endoscopy with standardized biopsies to screen for atrophic gastritis and intestinal metaplasia (found in 34% of CVID patients) if gastrointestinal symptoms are present.
•Refer to an immunologist for confirmation and initiation of immunoglobulin replacement therapy; coordinate a multidisciplinary approach including pulmonology, gastroenterology, and hematology for complicated cases.

Management

•Initiate immunoglobulin replacement therapy (IgRT) as soon as the diagnosis is confirmed. Start 400-600 mg/kg every 3-4 weeks or 100-200 mg/kg weekly; titrate the dose to maintain a trough IgG >700-800 mg/dL, though the ideal level should be individualized based on breakthrough infection frequency.
•SCIG is increasingly preferred for its flexibility, fewer systemic adverse effects, suitability for home administration, and improved quality of life. IVIG remains appropriate for patients who prefer center-based therapy or have adherence concerns.
•For breakthrough sinopulmonary infections despite adequate trough IgG levels, add antimicrobial prophylaxis: one double-strength tablet daily or 250 mg three times weekly. Tailor choice based on sputum culture results when possible.
•Manage GLILD with high-dose corticosteroids: initiate at ≥0.3 mg/kg daily (or equivalent). This regimen improves HRCT scores and forced vital capacity, achieving durable remission in approximately 42% of patients. Low-dose maintenance (<0.3 mg/kg) provides no added benefit, taper to the lowest effective dose over 4-8 weeks.
•For steroid-refractory or relapsing GLILD, use -based therapy. Low-dose rituximab 150 mg/m² weekly may achieve remission with fewer infections; standard-dose rituximab 375 mg/m² every 3 weeks is an alternative but carries a higher risk of opportunistic infections. Combination with azathioprine (dose per protocol) has shown benefit in case series.
•For autoimmune cytopenias (ITP, AIHA, Evans syndrome), first-line treatment is high-dose corticosteroids (e.g., pulse therapy). For refractory cases, consider rituximab, azathioprine, or other steroid-sparing immunosuppressants. Maintain IgG trough >7 g/L to reduce autoimmune thrombocytopenia episodes.
•In monogenic CVID due to haploinsufficiency, administer abatacept (CTLA-4 fusion protein) as targeted therapy. Hematopoietic stem cell transplantation (HSCT) can achieve sustained remission in 72% of CTLA-4 mutation carriers and is also an option for severe deficiency or other monogenic defects with refractory immune dysregulation.
•For LRBA deficiency, (mTOR inhibitor) has demonstrated efficacy in reducing lymphoproliferation and autoimmunity; consider HSCT if disease is severe and progressive.
•For refractory chronic spontaneous urticaria in CVID, can induce complete remission after the first injection and is well tolerated over 12 months.
•For malignancy arising in CVID (e.g., lung adenocarcinoma, lymphoma), (nivolumab, pembrolizumab) have been used successfully, achieving partial response with progression-free survival >15 months. Do not automatically exclude CVID patients from checkpoint inhibitor trials.
•Vaccination: administer inactivated influenza vaccine annually and mRNA vaccine series with boosters as recommended. Humoral responses develop in 52-83% of CVID patients but wane rapidly; T-cell responses are more durable and correlate with protection against severe disease. Live vaccines are contraindicated.
•Monitor for complications systematically: perform annual pulmonary function tests; repeat HRCT every 1-2 years if GLILD is present (consider MRI as radiation-sparing alternative); screen for gastric cancer with baseline upper endoscopy and standardized biopsies at diagnosis, then every 3-5 years (especially in smokers or with H. pylori infection).
•Intubation criteria for acute respiratory failure: FVC <20 mL/kg ideal body weight, PaO2/FiO2 ratio <150 mm Hg on non-rebreather, hypercapnia (PaCO2 >50 mm Hg with pH <7.30), or signs of impending fatigue (accessory muscle use, respiratory rate >35 breaths/min, abdominal paradox).
•Provide standard VTE prophylaxis for hospitalized CVID patients: 40 mg SC daily or 5000 U SC twice daily, unless bleeding risk from severe thrombocytopenia or active bleeding.
•Refer patients with complicated CVID (non-infectious complications, monogenic defect, refractory disease) to specialized immunology/transplant centers for consideration of targeted biologic therapies or HSCT.
•In pregnancy, continue IgRT to maintain trough IgG >500-700 mg/dL; IVIG is safe with no moderate/severe adverse effects. Coordinate multidisciplinary care with maternal-fetal medicine, immunology, and neonatology. Breastfeeding is encouraged as colostrum contains protective antibodies against enteropathogenic E. coli.
•In elderly patients, individualize IgG trough targets to balance infection prevention against volume overload; SCIG may be preferred to avoid hemodynamic stress of IVIG. Monitor for comorbidities (chronic lung disease, diabetes, hypertension) that complicate management.
•Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they exacerbate heart failure in patients with cardiac involvement. Avoid IgA-containing immunoglobulin products in patients with known anti-IgA antibodies at risk of anaphylaxis.
•Monitor for iatrogenic complications: corticosteroids increase opportunistic infection risk (2 cases in one series); rituximab may worsen humoral deficiency (compensated by IgRT); checkpoint inhibitors can trigger immune-related adverse events. Adjust immunosuppression in collaboration with the primary immunologist.

Board Review — High Yield

•Low IgG + IgA + impaired vaccine responses, Diagnostic triad for CVID; require onset after age 2 and exclusion of secondary causes.
•EUROclass smB- group, Switched memory B cells <2% of total B cells predicts splenomegaly, granulomatous disease, and lymphoma.
•CVIDc (complicated CVID), Presence of any non-infectious complication (cytopenias, lymphoproliferation, enteropathy) increases mortality 11-fold.
•NFKB1 haploinsufficiency, Most common monogenic cause (4% of Europeans); causes progressive B-cell defect, autoimmunity, and bronchiectasis.
•GLILD, Granulomatous-lymphocytic interstitial lung disease; diagnosed by HRCT + biopsy; treated with high-dose corticosteroids (≥0.3 mg/kg prednisone) ± rituximab.
•IVIG vs SCIG, Both first-line; SCIG has fewer systemic reactions and enables home therapy; target trough IgG >700-800 mg/dL.
•CTLA-4 insufficiency, Responds to abatacept; HSCT can be curative.
•Vaccination in CVID, Humoral responses blunted (52-83% seroconversion to COVID-19 mRNA vaccine, rapid waning); T-cell responses more durable; live vaccines contraindicated.
•Diagnostic delay, Averages 5-8 years; maintain high index of suspicion in adults with recurrent infections + autoimmunity or lymphoproliferation.
•Anaphylaxis risk, FCGR2A gain-of-function variant predisposes to IVIG reactions; switch to SCIG or use IgA-depleted products.

Deep Dive — Evidence Details

Definition, Classification & Immunodeficiency Defect Type

▸CVID is the most common symptomatic primary immunodeficiency in adults, defined by low immunoglobulins and impaired antibody responses.
▸Classification into infection-only (CVIDio) and complicated (CVIDc) phenotypes stratifies prognosis, with CVIDc carrying higher mortality from autoimmune, lymphoproliferative, and malignant complications.
▸Monogenic causes account for 20-30% of cases; NFKB1 loss-of-function is the most common in Europeans, but many patients lack an identifiable genetic variant.

HY High Yield: CVIDc is associated with TH1 polarization, expansion of cytotoxic CD4 TFH cells in lymph nodes, and defective germinal center formation [1,12].

Common Variable Immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency in adults, defined by low serum immunoglobulins (IgG and IgA and/or IgM) and impaired specific antibody responses, leading to recurrent infections, autoimmunity, lymphoproliferation, and increased malignancy risk ^[25]^D5.

Also Called: CVID, common variable immunodeficiency disorder, late-onset hypogammaglobulinemia.

Hypersensitivity Classification: CVID is not classified under the Gell-Coombs hypersensitivity schema. It is a primary immunodeficiency of humoral immunity, driven by defective B-cell differentiation and function. Many patients also exhibit T-cell dysregulation, including TH1 polarization ^[1]^C4 and expansion of a cytotoxic CD4 TFH-cell cluster in lymph nodes ^[12]^B3b, which accounts for the frequent autoimmune and inflammatory complications. Thus, CVID is best framed as a primary immunodeficiency involving both B- and T-cell compartments.

Clinical Phenotypes

The European Society for Immunodeficiencies (ESID) registry provides diagnostic criteria ^[15]^D5. Patients are broadly categorized into infection-only (CVIDio) and complicated CVID (CVIDc) ^[16]^B3b^[32]^C4.

Phenotype	Key Features	Clinical Implication
Infection-only	Recurrent sinopulmonary infections; no autoimmune or lymphoproliferative complications	Lower mortality; better prognosis ^[16]^B3b
Complicated (CVIDc)	Autoimmune cytopenias, lymphoproliferation (splenomegaly, lymphadenopathy), granulomatous disease, enteropathy	Higher mortality from infections and neoplasia; requires targeted immunosuppression ^[16]^B3b
Monogenic subtypes	Pathogenic variants in NFKB1 (most common in Europeans), CTLA4, LRBA, NFKB2, PIK3CD, TACI, BAFFR, CD19, ICOS, TRAF3, RAG2, IRF2BP2	Often autosomal dominant with variable penetrance; may guide therapy (e.g., CTLA-4 fusion protein) ^[6]^C4^[11]^C4^[17]^D5^[26]^C4^[30]^C4^[35]^D5^[37]^C4

Genetic Architecture: A monogenic cause is identified in approximately 20-30% of patients, most commonly heterozygous loss-of-function NFKB1 variants (4% of European CVID) ^[11]^C4^[27]^C4. These defects converge on impaired germinal center formation and B-cell class-switch recombination.

Clinical Significance: CVID carries substantial morbidity. Hepatic complications occur in 10% of hospitalizations and increase in-hospital mortality from 4% to 11% ^[19]^C4. Premature death is driven by infections and malignancy, particularly in CVIDc patients with lymphopenia, thrombocytopenia, or elevated liver enzymes ^[16]^B3b. Early immunoglobulin replacement therapy reduces infection frequency and improves survival ^[34]^C4.

Pearl: CVID is not a hypersensitivity disorder but a primary humoral immunodeficiency with frequent T-cell dysregulation; categorizing patients as infection-only versus complicated CVID (CVIDc) stratifies prognosis - CVIDc carries a higher risk of mortality from autoimmune and lymphoproliferative complications, and should trigger a thorough search for monogenic causes ^[6]^C4^[11]^C4^[16]^B3b.

Pathophysiology & Immune Mechanism

▸CVID results from a fundamental B-cell maturation defect compounded by T-cell dysregulation, with reduced switched memory B cells (<5/mL) identifying highest-risk patients.
▸A two-hit model, antibody deficiency permits microbial translocation, which then triggers unchecked monocyte/macrophage activation and interferon-driven cytokine cascades, drives non-infectious complications.
▸BTK is a central modifier of the inflammatory response to bacterial translocation; BTK inhibition attenuates this cascade, offering a potential therapeutic strategy.

The clinical phenotype of CVID arises from a fundamental failure of B-cell maturation and antibody production, compounded by T-cell dysregulation and chronic innate immune activation that drives the non-infectious complications which now dominate morbidity.

B-Cell Defects: The Core Humoral Failure

CVID is defined by hypogammaglobulinemia and defective specific antibody responses. The B-cell compartment shows a consistent maturational arrest: most patients have reduced numbers of class-switched memory B cells, and those with fewer than 5 switched memory B cells/mL are at highest risk for autoimmune cytopenias, splenomegaly, and granulomatous disease ^[77]^B2b. Genetic defects directly impair B-cell survival and class-switch recombination. Heterozygous variants in NFKB1, which encodes p105/p50 of canonical NF-κB signaling, are the most common monogenic cause of CVID, and patients carrying frameshift or nonsense variants have more autoimmune disease, bronchiectasis, and elevated plasma cytokines than those with missense variants ^[57]^B2b. Mutations in TACI (7-8% of CVID ^[69]^D5), LRBA ^[35]^D5^[41]^C4, CTLA4, IRF2BP2 ^[47]^C4, and hypomorphic RAG2 ^[30]^C4 all converge on impaired B-cell receptor signaling, defective class switching, or failure of peripheral B-cell tolerance. Despite profound , many CVID patients with autoimmune cytopenias produce autoreactive IgM antibodies that narrowly target erythrocyte i antigens and platelet i-related glycans, originating from marginal zone B cells activated outside germinal centers ^[51]^C4.

T-Cell Dysregulation and Follicular Skewing

T-cell abnormalities are common and clinically significant. In CVID patients with autoimmune cytopenias, circulating CD4+ T cells exhibit follicular helper T-cell features as early as thymic egress ^[42]^C4. This follicular skewing is driven by endotoxemia resulting from IgA deficiency: LPS induces activin A and inducible T-cell costimulator ligand, pushing naive T cells toward a follicular fate ^[42]^C4. The expanded circulating T follicular helper population provides efficient help to healthy donor B cells but cannot rescue the patient's own unresponsive B cells, and their aberrant cytokine receptor profiles interfere with regulatory T-cell suppression ^[42]^C4. Regulatory T-cell numbers and function are also reduced in CVID, particularly in those with autoimmune enteropathy ^[2]^B2a^[82]^D5. CD8+ T-cell compartment shows an accumulation of naive CD45RA+ cells and a deficiency of memory subsets, a pattern associated with vulnerability to opportunistic infections such as JC virus ^[46]^C4.

Microbial Translocation and Innate Immune Activation

A two-hit model best explains the inflammatory complications of CVID. First, insufficient neutralizing antibodies, especially IgA and anti-LPS antibodies, fail to contain commensal bacteria at mucosal surfaces, leading to translocation of microbial products such as lipopolysaccharide into the circulation ^[49]^B3b^[52]^B2b. Second, in genetically susceptible individuals, LPS triggers exaggerated monocyte/macrophage activation and a proinflammatory cytokine cascade. CVID patients with complications have elevated soluble CD14, CD163, neopterin, and robust upregulation of TNF-α, IL-6, IL-12p40, IFN-γ, CXCL9, and CXCL10 ^[49]^B3b^[74]^B3b^[83]^B3b. The tryptophan-kynurenine pathway is also activated, with increased kynurenine/tryptophan ratio and quinolinic acid correlating with systemic inflammation and B-cell phenotype ^[9]^C4. Notably, patients with X-linked agammaglobulinemia, who lack functional Bruton tyrosine kinase (BTK), are protected from this inflammatory cascade despite equivalent levels of bacterial translocation ^[52]^B2b. BTK inhibition recapitulates this protection ex vivo, identifying BTK as a central modifier of the systemic response to microbial translocation ^[52]^B2b.

Genetic and Epigenetic Contributions

Beyond the canonical CVID genes, several monogenic disorders present as CVID-like phenotypes. Gain-of-function variants in STAT3 produce a combined immunodeficiency with lymphoproliferation, enteropathy, and autoimmune cytopenias ^[44]^C4. IRF2BP2 deficiency impairs repression of NFAT, leading to enhanced proinflammatory cytokine expression and reduced B-cell maturation ^[47]^C4. Chromosome 18q deletions, FANC gene mutations, and hypomorphic IL2RG variants can all masquerade as late-onset CVID ^[66]^C4^[71]^C4^[40]^C4^[85]^D5. Epigenetic dysregulation also contributes: genome-wide DNA methylation changes in the duodenum of CVID patients with intraepithelial lymphocytosis distinguish their enteropathy from celiac disease and point to altered TNF/cytokine gene regulation ^[75]^C4. Familial studies show that B- and T-cell aberrancies are present in up to 60% of asymptomatic relatives, suggesting a broader heritable immune dysregulation spectrum ^[84]^C4.

Pearl: BTK is a central modifier of the inflammatory response to bacterial translocation; BTK inhibition attenuates this cascade, offering a potential therapeutic strategy.

Epidemiology, Etiology & Risk Factors

▸CVID is the most common symptomatic primary immunodeficiency, with a prevalence of 1 in 500 to 1 in 500,000 and a diagnostic delay of 5-8 years after first symptoms.
▸Heterozygous NFKB1 loss‑of‑function variants are the most frequent monogenic cause in Europeans (4% of cases), followed by CTLA4 haploinsufficiency (67% penetrance).
▸Celiac disease (aOR 17.25) and malignancy (overall 20.44% prevalence in CVID subgroups) are strongly associated, with lymphoma being the most common cancer.

HY High Yield: Diagnostic delay of 5-8 years is common; consider early genetic testing (especially NFKB1, CTLA4) in patients with CVID phenotype and autoimmune or lymphoproliferative features.

From these immune defects emerges a disorder whose true prevalence remains imprecisely defined, ranging from 1 in 500 to 1 in 500,000 depending on regional diagnostic capacity and registry infrastructure ^[25]^D5. CVID is the most frequent symptomatic primary immunodeficiency encountered in clinical practice, yet diagnostic delays of 5 to 8 years after the first cardinal symptom are the norm across all studied countries ^[91]^D5. The immune defect affects males and females equally, with most subjects diagnosed between the ages of 20 and 40 years ^[91]^D5. Pediatric CVID occurs as well, with a reported mean age at presentation of 8 years ^[21]^C4; in one Indian cohort the median diagnostic age was 18 years with a male predominance (62%) ^[29]^C4.

Genetic Etiologies

Heterozygous loss-of-function variants in are the most common monogenic cause of CVID in Europeans, accounting for 4% of cases in a large whole-genome sequencing study ^[11]^C4. These variants produce a temporally progressive defect in B‑cell differentiation and are associated with increased autoimmune disease, bronchiectasis, infections, and elevated plasma cytokines ^[57]^B2b. haploinsufficiency (heterozygous germline mutations) demonstrates a clinical penetrance of at least 67%, with hypogammaglobulinemia in 84% of affected carriers and a mortality rate of 16% ^[6]^C4. Other monogenic defects, including variants in (TACI), , , , and , collectively explain 20-30% of CVID in non‑consanguineous populations ^[17]^D5^[27]^C4. Skewed X‑chromosome inactivation may account for a small proportion of female cases (1.6-3.3%) ^[96]^B2b.

Environmental and Immune Triggers

Endotoxemia from microbial translocation is linked to early commitment to the follicular T‑cell lineage in IgA‑deficient CVID patients, particularly those with autoimmune cytopenias ^[42]^C4. This “two‑hit” model proposes that insufficient antibody neutralization of pathogen‑associated molecular patterns (e.g., LPS) combined with a heightened response to those mediators drives the cytokine dysregulation seen in CVID with non‑infectious complications ^[49]^B3b. Altered tryptophan‑kynurenine pathway metabolites, associated with systemic inflammation and B‑cell phenotype, further characterize the inflammatory environment ^[9]^C4.

Risk Factors for Associated Conditions

Factor	Odds Ratio / Hazard Ratio	Evidence Level
Nodular regenerative hyperplasia → mortality	HR 1.3 (95% CI 1.2-1.5) ^[19]^C4	4 (cross‑sectional)
→ mortality	HR 1.4 (95% CI 1.2-1.5) ^[19]^C4	4

Special Considerations

Infections often precede the diagnosis: pneumonia is the first disease manifestation in 31.6% of patients, and bronchiectasis is already present in 27-53% at diagnosis ^[92]^B2b^[99]^B2b. After SARS‑CoV‑2 infection, CVID patients have a strikingly high prevalence of Long COVID (65.7%), with fatigue, arthralgia, and dyspnea persisting in most cases ^[100]^B2b. Vaccination against COVID‑19 is safe and elicits measurable antibody responses in approximately 52% of CVID patients, though titers are lower and wane more rapidly than in healthy controls; T‑cell responses persist and correlate with protection against severe disease ^[59]^B2b^[62]^D5. No consistent seasonal variation in CVID onset is reported.

Pearl: Suspect CVID in any adult with recurrent sinopulmonary infections plus unexplained autoimmune cytopenia, splenomegaly, or enteropathy, the diagnostic delay remains 5-8 years even in high‑resource settings ^[91]^D5.

Clinical Presentation

▸Recurrent sinopulmonary infections are the most common presenting feature, but noninfectious complications, autoimmune cytopenias, lymphoproliferation, enteropathy, drive the 11‑fold increase in mortality [90].
▸Granulomatous‑lymphocytic interstitial lung disease (GLILD) occurs in up to 20% of patients and is predicted by splenomegaly, low IgA, history of ITP/AIHA, and elevated CD21low B cells [116].
▸Atypical presentations including JC virus‑related encephalopathy/retinopathy, Good syndrome (thymoma with hypogammaglobulinemia), and vaccine‑derived poliomyelitis must prompt genetic re‑evaluation [46][113][121].

! Warning: The presence of any single noninfectious complication (cytopenias, lymphoproliferation, or enteropathy) increases mortality 11-fold, do not dismiss these as incidental findings [90].

HY High Yield: Bronchiectasis is the most common structural lung complication; high‑resolution CT is the gold standard for detection, as plain radiography misses up to 59% of cases [118].

The clinical spectrum extends far beyond recurrent infections, encompassing autoimmune, lymphoproliferative, and malignant complications that together define the disease's morbidity and mortality ^[90]^D5.

Presenting Symptoms

Recurrent sinopulmonary infections dominate the initial presentation: 85% experience at least one acute respiratory episode, with pneumonia as the first manifestation in 32% ^[92]^B2b. Sinusitis (51%) and otitis media (43%) follow ^[92]^B2b. involvement affects 29-45% of patients, manifesting as chronic diarrhea, malabsorption, or weight loss; up to 29% have a formal diagnosis of CVID-associated enteropathy (CVID-E), which independently predicts gastrointestinal infections and cancer ^[102]^B3b. Autoimmune cytopenias, (ITP), (AIHA), or , occur in up to 62% of patients with monogenic forms (e.g., CTLA‑4 insufficiency) and often precede the immunodeficiency diagnosis ^[6]^C4^[78]^D5. Lymphoproliferation presents as splenomegaly (48%), generalized lymphadenopathy (24%), or mediastinal masses ^[11]^C4. The presence of even one noninfectious complication, cytopenias, lymphoproliferation, or enteropathy, carries an 11‑fold increase in mortality ^[90]^D5.

Phenotypic Variants

Variant	Key Features	Proportion of CVID
Infection-only	Recurrent sinopulmonary infections; no autoimmune or lymphoproliferative complications	~30-50% ^[90]^D5
Autoimmune cytopenias	ITP, AIHA, Evans syndrome; often with splenomegaly	~20-30% ^[61]^D5^[78]^D5
Polyclonal lymphoproliferation	Splenomegaly, lymphadenopathy, GLILD; elevated CD21low B cells	~20-30% ^[64]^C4^[116]^B3b
Enteropathy	Chronic diarrhea, malabsorption, nodular lymphoid hyperplasia; risk of GI malignancy	~15-30% ^[102]^B3b
Patients often evolve across phenotypes over years; a single patient may have overlapping features. The “CVID with complications” (CVIDc) group accounts for most premature mortality ^[16]^B3b.

Red Flags

Hepatopathy (CVID-L) and severe enteropathy are the strongest independent risk factors for death before age 70 ^[16]^B3b^[102]^B3b. Granulomatous‑lymphocytic (GLILD) affects up to 20% and is suggested by splenomegaly, low IgA (<13 mg/dL), history of ITP or AIHA, and expansion of CD21low B cells >5% (OR 5.8; AUC 0.86) ^[116]^B3b. Bronchiectasis develops in 27-73% of patients and correlates with diagnostic delay and CD4+ count <700 cells/μL ^[64]^C4^[92]^B2b. FVC <15 mL/kg or rapid decline on should prompt urgent evaluation for respiratory failure ^[118]^D5.

Atypical Presentations

CVID may first declare through rare but devastating infections: vaccine‑derived (poliovirus excretion for >10 years ^[113]^C4), progressive multifocal leukoencephalopathy due to JC virus (associated with naive CD8+ T‑cell accumulation ^[46]^C4), or JC virus‑related retinopathy ^[121]^C4. Good syndrome (thymoma with hypogammaglobulinemia) combines opportunistic infections (e.g., , ) with combined B‑ and T‑cell defects ^[45]^C4^[81]^C4. Cold‑induced urticaria, antibody deficiency, and autoimmunity characterize the PLCG2‑associated phenotype (familial cold autoinflammatory syndrome 3) ^[24]^C4. Other under‑recognized complications include pulmonary (group 5; median 12‑year delay from CVID diagnosis ^[28]^C4), AA amyloidosis secondary to chronic inflammation ^[119]^C4, and osteoporosis (prevalence ~41% at lumbar spine) ^[105]^C4.

Pearl: A CVID patient with one noninfectious complication (cytopenias, lymphoproliferation, or enteropathy) has an 11‑fold higher mortality than those with infections alone, these complications, not infection frequency, drive long‑term prognosis and demand aggressive multidisciplinary surveillance ^[90]^D5.

Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup

▸CVID diagnosis requires both low immunoglobulins and defective antibody responses; isolated low IgG without impaired vaccine response defines symptomatic IgG deficiency, not CVID.
▸Vaccine-response testing is essential and can be performed using ELISPOT even in patients receiving IVIG.
▸Genetic testing identifies monogenic causes in up to 10% of cases and may direct targeted therapies.

Dx Diagnostic Essentials: The gold standard for CVID diagnosis is the combination of low IgG and low IgA with impaired pneumococcal antibody response, after excluding secondary causes.

HY High Yield: In patients on IVIG, serologic vaccine response testing is unreliable. Use the anti-pneumococcal ELISPOT assay to detect functional antibody production [115].

The clinical suspicion raised by recurrent sinopulmonary infections, autoimmune cytopenias, or lymphoproliferation must be confirmed by objective laboratory criteria that capture both quantitative and qualitative humoral failure.

Diagnostic Criteria and Gold Standard

The diagnosis of CVID rests on the International Consensus Document (ICON) and European Society for Immunodeficiencies (ESID) criteria: (1) low serum IgG and low IgA (with or without low IgM), (2) impaired specific antibody responses to vaccination, (3) onset of immunodeficiency after age 2 years, and (4) exclusion of other secondary causes of hypogammaglobulinemia ^[111]^A1c. The gold standard is the combined demonstration of low immunoglobulins and defective antibody production, neither alone suffices.

Laboratory Studies

Immunoglobulin quantitation is the first step. Reduced IgG, IgA, and/or IgM below age-adjusted reference ranges is required. IgE levels should also be measured: IgE deficiency (<2.5 kU/L) in CVID carries a significantly higher malignancy risk (odds ratio 10.65 for prior malignancy) ^[93]^B2b.

Vaccine-response testing proves the qualitative defect. Measure pre- and 4‑week post-vaccination titers to pneumococcal polysaccharide (Pneumovax) and protein antigens ( , ). A poor response, failure to achieve a ≥2‑fold rise or protective levels in <70% of serotypes, defines the defect ^[114]^D5. For patients already on intravenous immunoglobulin (IVIG), serologic testing is unreliable; an ELISPOT assay measuring antibody-secreting cells after Pneumovax can distinguish true CVID from ^[115]^C4.

Serum B-cell maturation antigen (sBCMA) is a novel biomarker: a level <15 ng/mL has a 97% positive predictive value for CVID or X‑linked agammaglobulinemia, while ≥25 ng/mL has an 88% negative predictive value ^[127]^C4.

B-cell immunophenotyping by flow cytometry quantifies switched memory B cells (CD27+IgD-). Their marked reduction (<2% of B cells) is a hallmark of CVID and predicts noninfectious complications ^[88]^B2b^[110]^B3b. Expansion of CD21low B cells (>5%) correlates with granulomatous-lymphocytic (GLILD) and splenomegaly ^[116]^B3b.

T-cell analysis identifies late-onset combined immunodeficiency (LOCID), defined by low naive CD4+ T cells, which is independently associated with splenomegaly, lymphoma, and shortened survival ^[88]^B2b.

Allergy Testing

Patients with CVID often report atopic symptoms, yet standard skin prick testing and serum specific IgE can be falsely negative. In one study, only 9.7% of CVID patients had atopy by skin test, but bronchial provocation with allergen confirmed allergic asthma in 22.2% of those with suggestive histories ^[13]^C4. Therefore, bronchial challenge should be considered when clinical suspicion for asthma is high and standard tests are negative.

Genetic Testing

Monogenic causes account for up to 10% of CVID cases. The most common are heterozygous loss‑of‑function NFKB1 variants (4% of Europeans) ^[11]^C4, followed by mutations in CTLA4, LRBA, IKZF1, TCF3, TRAF3, and NFKB2 ^[8]^C4^[87]^C4^[117]^C4^[53]^C4^[26]^C4^[10]^D5. Genetic testing is indicated when noninfectious complications dominate (autoimmunity, lymphoproliferation, enteropathy), when there is a family history, or when atypical infections occur ^[44]^C4^[114]^D5. Identification of a specific defect can guide targeted therapy (e.g., abatacept for CTLA‑4 insufficiency, for mTOR pathway activation) ^[87]^C4^[131]^C4.

Diagnostic Algorithm

Quantitate immunoglobulins (IgG, IgA, IgM, IgE).
Assess vaccine responses, serology for pneumococcus and protein antigens (if not on IVIG); use ELISPOT if on IVIG.
Perform B‑cell and T‑cell immunophenotyping (switched memory B cells, CD21low B cells, naive CD4+ T cells).
Consider sBCMA if the diagnosis remains uncertain.
Genetic testing (targeted panel or whole exome) in patients with immune dysregulation, family history, or severe/atypical disease.

Once the diagnosis is confirmed, the next step is severity stratification to guide monitoring and .

Pearl: Genetic testing identifies monogenic causes in up to 10% of cases and may direct targeted therapies.

Core Diagnostic Laboratory Studies for CVID

Test	Finding	Clinical Implication
Serum IgG, IgA, IgM	IgG and IgA low (< age-adjusted reference)	Required for diagnosis; IgM may be low or normal ^[111]^A1c
Serum IgE	<2.5 kU/L	IgE deficiency associated with 10.65× odds of malignancy ^[93]^B2b
Pneumococcal vaccine response	<2-fold rise in <70% of serotypes	Confirms qualitative antibody failure ^[114]^D5
ELISPOT (anti-pneumococcal ASC)	No response after vaccination	Differentiates true CVID from IgG deficiency in patients on IVIG ^[115]^C4
Serum BCMA	<15 ng/mL	97% PPV for CVID or XLA ^[127]^C4
Switched memory B cells (CD27+IgD-)	<2% of B cells	Hallmark defect; predicts noninfectious complications ^[88]^B2b^[110]^B3b
CD21low B cells	>5% of B cells	Associated with GLILD, splenomegaly ^[116]^B3b
Naive CD4+ T cells	Low (age-adjusted)	Defines LOCID; linked to lymphoma and reduced survival ^[88]^B2b

Severity, Grading & Risk Stratification

▸The EUROclass B-cell classification stratifies CVID patients into prognostic groups: reduced switched memory B cells (<2%) and/or expanded CD21low B cells (>10%) define a high-risk phenotype associated with non-infectious complications and reduced survival.
▸Clinical phenotypes (infection-only vs. infection plus autoimmunity/lymphoproliferation/enteropathy) carry markedly different prognoses; the presence of any non-infectious complication increases mortality 11-fold.
▸Monogenic forms (NFKB1, NFKB2, CTLA4, LRBA) often have distinct risk profiles that inform targeted therapy (e.g., abatacept in CTLA-4 insufficiency) and consideration of hematopoietic stem cell transplantation.

HY High Yield: The presence of any non-infectious complication is the single strongest predictor of mortality in CVID, increasing risk 11-fold [90].

Once the diagnosis is confirmed, the clinician must stratify the patient's risk, a process that directly determines surveillance intensity, treatment selection, and prognosis. CVID is not a single entity; its clinical and immunologic heterogeneity demands a structured approach to grading.

Clinical Phenotype-Based Stratification

The simplest and most powerful stratification begins with the clinical phenotype. Patients can be grouped into those with infection-only disease and those who also develop non-infectious complications (autoimmune cytopenias, lymphoproliferation, enteropathy, granulomatous disease, or malignancy). The presence of even one non-infectious complication increases mortality 11-fold compared with infection-only disease ^[90]^D5. Non-infectious complications occur in 50-60% of patients and are the primary drivers of morbidity and mortality ^[88]^B2b^[90]^D5.

Clinical Phenotype	Defining Features	Risk Level
Infection-only	Recurrent sinopulmonary infections, no autoimmune or lymphoproliferative disease	Standard
Autoimmune	Autoimmune cytopenias (ITP, AIHA), organ-specific autoimmunity	High
Lymphoproliferative	Splenomegaly, lymphadenopathy, granulomatous-lymphocytic (GLILD)	High
Enteropathic	Chronic diarrhea, villous atrophy, norovirus-driven inflammation	High
Malignancy	Lymphoma (especially B-cell), gastric carcinoma	Very high

Immunologic Biomarkers for Risk Stratification

B-cell subset analysis refines the risk beyond clinical phenotyping. The EUROclass classification stratifies patients by switched memory B-cell (smB) frequency and CD21low B-cell expansion:

EUROclass Group	Definition	Prognostic Association
SmB<sup>-</sup>	smB <2% of total B cells	Higher risk of splenomegaly, granulomatous disease, lymphoma ^[88]^B2b
CD21<sup>low</sup><sup>high</sup>	CD21<sup>low</sup> B cells >10%	Marked risk of lymphoproliferation, splenomegaly, poor vaccine response ^[142]^B2b
SmB<sup>+</sup>/CD21<sup>low</sup><sup>norm</sup>	Normal smB and CD21<sup>low</sup>	Favorable prognosis, infection-only phenotype

Additional biomarkers stratify risk independently: undetectable IgE (<2 kU/L) is associated with a higher frequency of autoimmune cytopenias and lymphoma ^[150]^B2b; elevated serum CXCL13 correlates with the number of clinical complications and identifies patients with complex disease ^[153]^B3b; and late-onset combined immunodeficiency (LOCID), defined by CD4+ naive T cells <20% of total CD4+ cells, is independently associated with splenomegaly, lymphadenopathy, interstitial lung disease, cytopenia, and lymphoma ^[88]^B2b. A machine-learning model incorporating Th-Tc ratio, CD19 count, and IgM level predicted severe disease (Ameratunga clinical severity score) with an accuracy of 0.853 ^[29]^C4.

Genetic Stratification

Monogenic causes are identified in approximately 20-30% of patients in nonconsanguineous populations ^[17]^D5. Each gene defect carries a distinct risk profile:

NFKB1 haploinsufficiency (autosomal dominant, incomplete penetrance ~70%): high rates of autoimmunity (57%), lymphoproliferation (52%), and malignancy (17%) ^[8]^C4. Patients may develop EBV-driven lymphoproliferative disease ^[151]^C4.
NFKB2 loss-of-function (autosomal dominant): risk of fatal enteroviral encephalitis, absent B cells and germinal centers ^[152]^C4.
CTLA-4 insufficiency (autosomal dominant): life-threatening autoimmune and lymphoproliferative complications; responds to abatacept and may be cured by HSCT ^[87]^C4.
LRBA deficiency (autosomal recessive): early-onset severe disease; premature stop codons predict earlier presentation, severe autoimmunity, and premature death ^[35]^D5.

Identifying a monogenic cause shifts from supportive immunoglobulin replacement toward targeted immunosuppression (e.g., abatacept in CTLA-4 insufficiency) and consideration of hematopoietic stem cell transplantation ^[8]^C4^[87]^C4^[149]^B2b.

Complications-Based Severity Grading

Organ-specific complications define additional risk strata. GLILD, a distinct clinico-radio-pathological entity, requires dedicated screening with high-resolution CT and , as it is associated with early mortality ^[147]^A1c^[126]^D5. Risk factors for GLILD include CVID diagnosis and increased CD4 effector/memory cells ^[148]^B2b. Chronic kidney disease occurs in 6.8% of PAD patients and is linked to a more severe immunophenotype (lower CD4, CD19, and smB counts) ^[145]^B2b. Osteoporosis is present in over 40% of CVID patients, particularly those with bronchiectasis and lower lung function ^[105]^C4. Sleep-disordered breathing affects 77% of screened patients and contributes to fatigue and reduced quality of life ^[98]^C4.

Controversies and Guideline Disagreement

No major guideline disagreement exists regarding the core stratification principles, but the optimal frequency and method for GLILD screening remain debated. The 2026 ERS guideline recommends screening all adult CVID patients with HRCT (conditional recommendation), whereas the UK consensus statement (2017) did not achieve consensus on expectant management versus routine screening ^[126]^D5^[147]^A1c.

Pearl: The presence of any single non-infectious complication, autoimmune cytopenia, lymphoproliferation, or enteropathy, confers an 11-fold increase in mortality and should trigger intensified surveillance for GLILD, lymphoma, and other organ-specific complications, as well as early consideration of immunosuppressive therapy ^[90]^D5.

EUROclass B-Cell Subset Stratification

EUROclass Group	Definition	Prognostic Association
SmB-	smB <2% of total B cells	Higher risk of splenomegaly, granulomatous disease, lymphoma ^[88]^B2b
CD21low high	CD21low B cells >10%	Marked risk of lymphoproliferation, splenomegaly, poor vaccine response ^[142]^B2b
SmB+/CD21low norm	Normal smB and CD21low	Favorable prognosis, infection-only phenotype

Acute Management & Anaphylaxis Pathway

▸Intramuscular epinephrine is the first-line treatment for anaphylaxis in CVID; do not delay administration.
▸The FCGR2A(c.742+871A>G) mutation increases risk of anaphylactoid reactions to IVIG and should be considered in patients with recurrent infusion reactions.
▸Switching to subcutaneous immunoglobulin (SCIG) reduces systemic reactions and is a safe alternative for patients with CVID who experience infusion-related anaphylaxis.

Rx Drug of Choice: Intramuscular epinephrine is the drug of choice for anaphylaxis in CVID. Administer immediately upon recognition, do not wait for adjunctive therapies.

! Warning: Do not use antihistamines or corticosteroids as first-line treatment for anaphylaxis; they do not reverse airway obstruction or hypotension. Epinephrine is the only life-saving intervention.

Once severity and risk stratification are established, the immediate priority shifts to managing acute hypersensitivity reactions, particularly , which can occur during immunoglobulin replacement therapy or other exposures. In patients with CVID, anaphylaxis is a rare but life-threatening event, with a distinct genetic predisposition identified in a subset of individuals ^[158]^C4. The following pathway outlines the time-critical steps for recognition and intervention.

Step 1: Recognition and Immediate Intervention

Anaphylaxis should be suspected when any of the following occur within minutes to hours after exposure to a trigger (most commonly IVIG, but also SCIG, vaccines, or blood products): sudden onset of urticaria, , respiratory distress (wheezing, stridor), hypotension, or symptoms (cramping, vomiting). Immediate administration of intramuscular epinephrine is the first-line treatment, do not delay for adjunctive therapies. Place the patient supine with legs elevated if hypotensive. Call for emergency support and remove the offending agent if still infusing.

Step 2: CVID-Specific Risk Factors and Prevention

Patients with CVID may carry the FCGR2A(c.742+871A>G) mutation, which encodes a gain-of-function FcγRIIa splice variant associated with anaphylactoid reactions to IVIg ^[158]^C4. This allele is more frequent in CVID than in the general population and should be considered in patients with recurrent infusion reactions. For those with known IgA deficiency (a common comorbidity), use IgA-depleted immunoglobulin products to minimize the risk of anti-IgA-mediated anaphylaxis. Premedication with antihistamines, acetaminophen, and corticosteroids may reduce the frequency of mild-to-moderate infusion reactions, though evidence for preventing true anaphylaxis is limited.

Step 3: of Infusion Reactions

For mild reactions (flushing, headache, mild urticaria): slow the infusion rate by 50% and administer an oral antihistamine (e.g., diphenhydramine 25-50 mg). If symptoms resolve, the infusion may be resumed at a slower rate. For moderate reactions (generalized urticaria, mild wheezing): stop the infusion, administer intramuscular epinephrine and an antihistamine, and monitor closely. For severe anaphylaxis (hypotension, respiratory compromise): stop the infusion immediately, administer epinephrine intramuscularly, call for advanced life support, and transfer to an emergency department. After recovery, consider switching to subcutaneous immunoglobulin (SCIG), which is associated with fewer systemic reactions and improved tolerability in patients with CVID ^[133]^D5^[156]^C4.

Step 4: Monitoring and Follow-Up

After an anaphylactic episode, observe the patient for at least 4-6 hours for biphasic reactions. Prescribe an epinephrine auto-injector and provide a written emergency action plan. Refer to an allergist/immunologist for consideration of desensitization if immunoglobulin therapy is essential and no alternative route is feasible. Document the reaction in the patient's record and consider genetic testing for the FCGR2A variant if recurrent reactions occur ^[158]^C4.

Step 5: Transition to Long-Term Management

Once the acute event is resolved, the focus shifts to preventing future episodes. This includes optimizing immunoglobulin dosing and route, using premedication protocols, and addressing any underlying autoimmune or lymphoproliferative complications that may increase hypersensitivity risk. The next section details long-term strategies including avoidance, immunotherapy, and biologic therapies.

Pearl: In CVID patients with anaphylaxis to IVIG, check for the FCGR2A gain-of-function variant and consider switching to SCIG, which reduces systemic reaction rates and improves quality of life ^[133]^D5^[156]^C4^[158]^C4.

Management of Immunoglobulin Infusion Reactions in CVID

Reaction Severity	Symptoms	Immediate Action	Follow-Up
Mild	Flushing, headache, mild urticaria	Slow infusion rate by 50%; give oral antihistamine	Resume at slower rate if symptoms resolve
Moderate	Generalized urticaria, mild wheezing	Stop infusion; give IM epinephrine + antihistamine	Monitor; consider SCIG switch
Severe	Hypotension, respiratory distress, angioedema	Stop infusion; give IM epinephrine; call emergency services	Transfer to ED; observe for biphasic reaction

Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics

▸Non-infectious complications of CVID (autoimmune cytopenias, lymphoproliferation, enteropathy) increase mortality 11-fold and require targeted immunosuppression.
▸High-dose corticosteroid induction (≥0.3 mg/kg prednisone) is first-line for GLILD, achieving ~42% long-term remission; low-dose maintenance offers no benefit.
▸Rituximab-based therapy (with or without azathioprine) is the best-validated second-line option for GLILD, though optimal dosing remains unclear.
▸Biologic agents (omalizumab for CSU, dupilumab for CADINS, PD-1 inhibitors for malignancy) can be effective in selected CVID patients despite underlying immunodeficiency.

HY High Yield: For GLILD, the STILPAD study showed that only 42% of patients achieved long-term remission after high-dose corticosteroid induction, and low-dose maintenance did not improve outcomes [139].

! Warning: Standard-dose rituximab (375 mg/m² every 3 weeks) in CVID patients with lymphoid interstitial pneumonia was associated with a higher incidence of opportunistic infections compared with low-dose therapy (150 mg/m² weekly) [187].

Once acute hypersensitivity reactions are controlled and immunoglobulin replacement is established, the clinician's focus shifts to the non-infectious complications that dominate long-term morbidity and mortality in CVID, autoimmune cytopenias, lymphoproliferation, granulomatous disease, and malignancy ^[90]^D5. The presence of even one of these phenotypes (cytopenias, lymphoproliferation, or enteropathy) confers an 11-fold increase in mortality ^[90]^D5. therefore requires a parallel strategy of immunosuppression, targeted biologics, and active surveillance, all layered over the infection-prevention foundation.

Step 1: Initial Assessment and Severity Classification

Classify the dominant complication. For granulomatous-lymphocytic (GLILD), obtain baseline high-resolution CT (HRCT) and (PFTs), including forced vital capacity (FVC) and diffusing capacity (DLCO). MRI offers a radiation-sparing alternative for follow-up, with concordance to CT for consolidations, nodules, and bronchial wall thickening, though it is less sensitive for bronchiectasis extension ^[182]^C4. For autoimmune cytopenias, confirm with , direct antiglobulin test, and bone marrow biopsy if cytopenias persist. For granulomatous disease affecting the central nervous system, MRI brain with leptomeningeal enhancement is indicated ^[178]^C4. Severity of GLILD is graded by Hartman score on HRCT and PFT impairment; severe disease is defined by DLCO <50% predicted or rapid decline in FVC.

Step 2: First-Line Interventions

GLILD, Initiate high-dose corticosteroids at ≥0.3 mg/kg equivalent daily ^[139]^C4. In a multicenter analysis of 56 treated patients (STILPAD study), this regimen significantly improved HRCT scores and FVC; DLCO improved in both treatment and control groups. Among 18 patients with extended follow-up, 13 achieved long-term, maintenance therapy-independent remission, but only 42% overall (13 of 31 evaluable) achieved durable remission. Relapse occurred in 5 patients; only 1 of 5 responded to retreatment. Low-dose maintenance (<0.3 mg/kg) provided no added benefit ^[139]^C4. Autoimmune cytopenias, First-line high-dose corticosteroids (e.g., pulse therapy) are standard ^[186]^C4. For refractory chronic spontaneous urticaria (CSU) in CVID, omalizumab produced complete remission after the first injection and was well-tolerated over 12 months ^[185]^C4.

Step 3: Second-Line and Biologic Therapy

When corticosteroids fail or are poorly tolerated, -based regimens are the best-supported alternative for GLILD. In a retrospective series of 7 patients, rituximab + azathioprine (dose not specified) improved FEV1 (p=0.034) and FVC (p=0.043) and reduced HRCT scores for consolidations, ground-glass opacities, nodular opacities, and bronchial wall thickening, with no significant chemotherapy-related complications ^[141]^C4. In another case, rituximab 150 mg/m² weekly (low dose) induced temporary remission in lymphoid interstitial pneumonia with decreased paraproteinemia and β2-microglobulin; however, standard-dose rituximab (375 mg/m² every 3 weeks) failed to achieve longer remission and increased opportunistic infections ^[187]^C4. For patients with CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS), a monogenic form that mimics CVID, dupilumab (a monoclonal antibody blocking IL-4/IL-13 signaling) markedly improved severe eczema ^[184]^C4. For malignancy (e.g., lung adenocarcinoma) arising in a patient with CVID and B-cell deficiency, PD-1 inhibitor therapy (e.g., or ) achieved partial response with progression-free survival exceeding 15 months and no serious adverse events, challenging the historical exclusion of such patients from checkpoint inhibitor trials ^[188]^C4.

Step 4: Monitoring and Titration

Monitor GLILD response with repeated HRCT and PFTs every 6 months; consider MRI for radiation-sensitive patients ^[182]^C4. For autoimmune cytopenias, follow hemoglobin, platelet count, and transfusion requirements. Taper corticosteroids to the lowest effective dose over 4-8 weeks; if unable to wean, escalate to a steroid-sparing agent. For rituximab, track B-cell counts (CD19) and serum immunoglobulins, profound B-cell depletion may worsen humoral deficiency, but immunoglobulin replacement compensates. Infection surveillance is essential: two opportunistic infections occurred in the corticosteroid cohort ^[139]^C4, and rituximab use increased infection risk, particularly with standard dosing ^[187]^C4.

Step 5: Transition and Long-Term Strategies

Once remission is achieved and stable, step down immunotherapy to the minimal effective regimen. Low-dose corticosteroid maintenance is not beneficial in GLILD ^[139]^C4. For patients with recurrent relapse, consider rituximab retreatment, but efficacy declines ^[139]^C4. In all patients, avoid unnecessary radiation exposure, as radiosensitivity is a concern in certain CVID subgroups ^[182]^C4. HPV vaccination in adolescence and regular cervical cytology is recommended for CADINS patients due to malignancy risk ^[184]^C4. Close coordination with the managing immunologist ensures that immunosuppression does not undermine immunoglobulin replacement, the subject of the next section.

Dosing and Evidence Table

Drug/Modality	Indication	Dose (from cited evidence)	Key Findings	Evidence Level
Prednisone (corticosteroid)	GLILD	≥0.3 mg/kg daily	Improved HRCT score and FVC; 42% long-term remission ^[139]^C4	4 (case series)
Rituximab + azathioprine	GLILD	Not specified in abstract	Improved FEV1, FVC, HRCT scores; no serious complications ^[141]^C4	4 (retrospective)
Rituximab (low-dose)	LIP in CVID	150 mg/m² weekly	Temporary remission; decreased paraproteinemia ^[187]^C4	4 (case report)
Rituximab (standard-dose)	LIP in CVID	375 mg/m² every 3 weeks	Shorter remission; higher infection rate ^[187]^C4	4 (case report)
Omalizumab	Refractory CSU in CVID	Not specified in abstract	Complete remission after first injection ^[185]^C4	4 (case report)
Dupilumab	Severe eczema in CADINS	Not specified in abstract	Marked improvement of eczema ^[184]^C4	4 (case report)
PD-1 inhibitor	Malignancy (lung adenocarcinoma)	Not specified in abstract	Partial response; PFS >15 months ^[188]^C4	4 (case report)

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
Optimal rituximab dosing for GLILD	Low-dose (150 mg/m² weekly) may achieve remission with fewer infections ^[187]^C4	Standard-dose (375 mg/m²) is used in other autoimmune conditions but may increase infection risk ^[187]^C4	Mild (conflicting single-case evidence)	Individualize based on infection history; consider low-dose escalation.
First-line for GLILD	Corticosteroids alone are recommended as first-line ^[139]^C4	Combination rituximab-azathioprine is used early in some centers ^[141]^C4	Moderate (no RCT; different institutional practices)	Corticosteroids remain standard; combination reserved for steroid-refractory disease.

No major guideline bodies have issued formal recommendations for these off-label uses; evidence is Level 4 throughout. Future prospective studies are needed.

Pearl: For GLILD, high-dose corticosteroid induction (≥0.3 mg/kg prednisone) achieves durable remission in ≈ of patients, but low-dose maintenance provides no benefit; rituximab-based therapy is effective second-line, though rituximab standard dosing (375 mg/m²) may increase infection risk compared with a low-dose (150 mg/m² weekly) approach ^[139]^C4^[141]^C4^[187]^C4.

Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution

▸Initiate IgRT (IVIG or SCIG) at diagnosis; dose titration to an individual protective trough level is essential.
▸Antimicrobial prophylaxis is added for breakthrough respiratory infections despite optimized IgRT.
▸HSCT offers cure in select monogenic CVID-like disorders (CTLA-4, LRBA) but not in classic CVID without a defined genetic cause.

Rx Drug of Choice: First-line: Immunoglobulin replacement therapy (IVIG or SCIG), start at 400-600 mg/kg/month IVIG or 100-200 mg/kg/week SCIG [133].

For patients with CVID, immunoglobulin replacement therapy (IgRT) remains the cornerstone of infection prevention and is initiated as soon as the diagnosis is confirmed. The goal is to maintain serum IgG trough levels above the individual's protective threshold, typically >700-800 mg/dL, though the ideal level varies ^[133]^D5 ^[134]^D5. Therapy is delivered either intravenously (IVIG) or subcutaneously (SCIG). Standard starting doses are IVIG 400-600 mg/kg every 3-4 weeks or SCIG 100-200 mg/kg weekly; dose is then titrated based on breakthrough infections and trough levels ^[133]^D5 ^[134]^D5. SCIG is increasingly preferred for its flexibility, fewer systemic adverse effects, and suitability for home administration, particularly in patients with difficult venous access or previous thrombotic events ^[159]^C4 ^[133]^D5. Patients on IVIG in the CKD group in one series were more likely to receive IVIG, suggesting that route selection may influence renal outcomes and warrants monitoring ^[94]^B2b (2b).

Option	Route	Typical Starting Dose	Key Advantage	Key Monitoring
IVIG	Intravenous	400-600 mg/kg q3-4wk	Hospital/center-based, high peak levels	Trough IgG, renal function, infusion reactions
SCIG	Subcutaneous	100-200 mg/kg weekly	Home therapy, fewer systemic AEs	Trough IgG, local site reactions

Step 3: Antimicrobial Prophylaxis

Even with optimized IgRT, breakthrough respiratory infections occur, often viral (56% of exacerbations) ^[125]^C4 (4). For patients with recurrent sinopulmonary infections despite adequate trough levels, prophylactic (e.g., or ) reduce exacerbation frequency ^[94]^B2b ^[125]^C4. Antibiotic use should be guided by sputum culture when possible; purulent sputum responds well to targeted therapy, while isolated sore throat often does not ^[125]^C4. In special populations (pregnancy), coordinated multidisciplinary care with IgRT dose adjustment is critical to maintain maternal protection and optimize placental IgG transfer ^[137]^D5 (5). mRNA vaccines are safe in CVID but show diminished antibody responses, especially in patients with noninfectious complications; a third dose rarely seroconverts prior non-responders, making continued infection prevention strategies essential ^[190]^B2b (2b) ^[193]^B2b (2b).

Step 4: Immune Reconstitution: HSCT and Gene Therapy

Hematopoietic stem cell transplantation (HSCT) offers a potential cure for selected patients with monogenic CVID-like disorders such as CTLA-4 insufficiency, LRBA deficiency, or NFKB1 haploinsufficiency ^[87]^C4 ^[120]^C4. In an international cohort of CTLA-4 mutation carriers, HSCT achieved sustained remission in 72% of patients (13/18) ^[87]^C4 (4). For classic CVID without an identifiable monogenic cause, HSCT is rarely indicated due to high risk of graft-versus-host disease and uncertain benefit; gene therapy remains experimental with no approved CVID-specific vector ^[48]^D5 (5). Abatacept, , and are targeted immunosuppressants for associated autoimmune lymphoproliferation, but do not replace IgRT for infection prophylaxis ^[87]^C4 ^[131]^C4.

Controversies in Practice

The optimal IgG trough target remains debated: some centers aim for >800 mg/dL, while others individualize based on infection history ^[133]^D5 ^[134]^D5. The choice between IVIG and SCIG is driven by patient preference, adherence, and adverse effect profile; no -to-head trial has demonstrated superiority in infection prevention ^[133]^D5.

Pearl: Start immunoglobulin replacement at diagnosis, titrate the dose to an individualized trough that prevents breakthrough infections, and add antimicrobial prophylaxis for persistent sinopulmonary infections, HSCT is reserved for patients with defined monogenic defects who have refractory immune dysregulation ^[87]^C4 ^[133]^D5.

Complications, Comorbidities & Iatrogenic Risks

▸Noninfectious complications, autoimmune cytopenias, enteropathy, lymphoproliferation, and malignancy, now dominate CVID morbidity and mortality, with even one complication conferring an 11-fold increase in death risk.
▸Bronchiectasis affects 27-53% of patients with an accelerated FEV₁ decline of 25 mL/year; GLILD requires HRCT, biopsy, and often immunosuppression beyond immunoglobulin replacement.
▸Malignancy occurs in 20% of CVID patients (lymphoma > carcinoma), with head and neck cancer incidence increased over 6-fold; vaccination responses are impaired and wane rapidly.

HY High Yield: The combination of autoimmune cytopenia, lymphoproliferation, and enteropathy defines a high-risk CVID phenotype with 11-fold increased mortality; these patients require aggressive surveillance and early immunomodulatory therapy [90].

The evolution of immunoglobulin replacement and antimicrobial prophylaxis has shifted the clinical trajectory of CVID: noninfectious complications, immune dysregulation, autoimmunity, lymphoproliferation, and malignancy, now drive most morbidity and mortality ^[16]^B3b^[90]^D5. The presence of even one complication among cytopenias, lymphoproliferation, or enteropathy confers an 11-fold increase in mortality ^[90]^D5.

Immune Dysregulation and Autoimmunity

Autoimmune cytopenias (immune thrombocytopenia, , or ) are the most common autoimmune manifestations, occurring in up to 62% of patients with CTLA-4 insufficiency ^[6]^C4 and frequently as part of CVID ^[61]^D5^[78]^D5. Organ-specific autoimmunity affects the tract (enteropathy, atrophic gastritis), joints (arthritis), skin ( in 8.5%, eczema in 22.4%), and lungs ^[61]^D5^[201]^C4. Underlying mechanisms include defective B-cell tolerance with expanded autoreactive VH4-34 clones, elevated BAFF: TACI ratio, and interferon-/inflammasome-driven monocyte activation ^[83]^B3b^[138]^C4. Heterozygous NFKB1 loss-of-function variants further amplify autoimmune disease, bronchiectasis, and gastrointestinal infections ^[57]^B2b^[204]^D5.

Respiratory Complications and Monitoring

Bronchiectasis affects 27% to 53% of patients and is associated with an annual FEV₁ decline of 25 mL/year (vs 8 mL/year without bronchiectasis) and lower quality of life ^[92]^B2b^[99]^B2b. Granulomatous-lymphocytic (GLILD) occurs as a distinct clinico-radio-pathological entity requiring HRCT and lung biopsy for diagnosis ^[126]^D5.

Table: Intubation Criteria in CVID with Acute Respiratory Failure

Parameter	Threshold	Rationale [N]
FVC	< 20 mL/kg ideal body weight	Predicts inability to clear secretions [standard]
PaO₂/FiO₂ ratio	< 150 mm Hg on non-rebreather	Severe hypoxemic failure [standard]
Hypercapnia	PaCO₂ > 50 mm Hg with acidosis (pH < 7.30)	Alveolar hypoventilation [standard]
Work of breathing	Accessory muscle use, abdominal paradox, respiratory rate > 35	Impending fatigue [standard]

Gastrointestinal and Hepatic Complications

Chronic enteropathy presents with diarrhea and malabsorption; infections with norovirus, Giardia, Campylobacter, or cytomegalovirus must be distinguished from noninfectious inflammatory disease ^[197]^D5. Hepatic complications occur in 10% of hospitalizations, steatosis (38%), cirrhosis (24%), (15%), nodular regenerative hyperplasia (14%), and are associated with 11% in-hospital mortality and longer stays ^[19]^C4. Hepatopathy and severe enteropathy are the strongest premortem predictors of early death ^[16]^B3b.

Malignancy Risk

Malignancy prevalence reaches 20.4% in CVID subgroups, with lymphoma (especially ) as the leading type (40.5% of all cancers), followed by carcinomas (35.1%) ^[97]^C4. risk is elevated (standardized incidence ratio 6.55, 95%) and carries higher postoperative mortality ^[108]^B3b. NFKB1 variant carriers also show increased gastric cancer ^[6]^C4.

Hospital-Acquired and Iatrogenic Complications

Hospitalized CVID patients require standard VTE prophylaxis with 40 mg SC daily or 5000 U SC twice daily (unless bleeding risk from cytopenias). Pain is multimodal: abdominal pain from enteropathy often responds to antimicrobials for identified pathogens ^[197]^D5; arthritis and neuropathic pain require NSAIDs or gabapentinoids with careful renal monitoring. Early pulmonary rehabilitation improves exercise capacity in bronchiectasis and GLILD ^[56]^D5. Infection prevention includes hand hygiene, pressure injury risk assessment, and avoidance of unnecessary urinary catheters.

Corticosteroids used for GLILD (≥0.3 mg/kg/day equivalent) improve HRCT scores and FVC but carry risk of opportunistic infection (2 cases in one series) and poor response in relapsed disease ^[139]^C4. and abatacept are effective second-line options for GLILD and CTLA-4 insufficiency, but require monitoring for EBV reactivation ^[6]^C4^[87]^C4^[131]^C4. Hematopoietic stem cell transplantation achieves cure in 72% of CTLA-4-insufficient patients but carries transplant-related mortality ^[87]^C4. Vaccination responses are blunted: only 16.7% achieve seroprotective influenza antibody titers ^[140]^C4, and mRNA vaccine seroconversion wanes from 52% at 1 month to **** at 6 months, with T-cell responses more durable ^[59]^B2b^[190]^B2b.

Pearl: Malignancy occurs in 20% of CVID patients (lymphoma > carcinoma), with and neck cancer incidence increased over 6-fold; vaccination responses are impaired and wane rapidly.

Intubation Criteria in CVID with Acute Respiratory Failure

Parameter	Threshold	Rationale
FVC	< 20 mL/kg ideal body weight	Predicts inability to clear secretions
PaO₂/FiO₂ ratio	< 150 mm Hg on non-rebreather	Severe hypoxemic failure
Hypercapnia	PaCO₂ > 50 mm Hg with acidosis (pH < 7.30)	Alveolar hypoventilation
Work of breathing	Accessory muscle use, abdominal paradox, respiratory rate > 35	Impending fatigue

Prognosis & Natural History

▸Survival in CVID is determined primarily by noninfectious complications, not infection burden alone [16].
▸Lower serum IgG, marked CD27+ memory B cell deficiency (27MBC-), and late-onset combined immunodeficiency are strong independent predictors of early death [88].
▸Hepatopathy, severe enteropathy, lymphopenia, and thrombocytopenia are associated with premature mortality before age 70 years [16].

While complications dominate the clinical picture, the natural history of CVID is heterogeneous, and survival is determined largely by the presence and severity of noninfectious complications rather than by infection burden alone ^[16]^B3b. In a large cohort of 497 patients, 57 (11.5%) had died; the most common causes of death were infections and neoplasia ^[16]^B3b. Patients with CVID and noninfectious complications (CVIDc) had significantly higher mortality than those with infection-only presentation ^[16]^B3b.

Mortality and Causes of Death

Cancer is a leading contributor: CVID accounted for the highest number of reported malignancy cases (1284) among inborn errors of immunity, with diffuse large B‑cell lymphoma as the most frequent histology ^[86]^A1a. Among IEI patients with cancer, 55.6% (1173/2110) succumbed to their malignancy ^[86]^A1a. In a pediatric CVID cohort, severe complications and poor outcome clustered in patients lacking memory B cells ^[34]^C4.

Prognostic Biomarkers

Marker	Association with Outcome	Source
Lower serum IgG, late‑onset combined immunodeficiency (LOCID), marked CD27⁺ memory B cell defect (27MBC⁻)	Strongly associated with shorter survival and early death ^[88]^B2b	^[88]^B2b
Hepatopathy, severe enteropathy, lymphopenia, thrombocytopenia, elevated liver enzymes	Premature death before age 70 years ^[16]^B3b	^[16]^B3b
NFKB1 loss‑of‑function variants (4 % of CVID)	Associated with lymphadenopathy (24 %), splenomegaly (48 %), autoimmune disease (48 %), features linked to worse prognosis ^[11]^C4	^[11]^C4
IKZF1 haploinsufficiency	CVID or combined immunodeficiency with hematologic manifestations ^[210]^D5	^[210]^D5

Pulmonary Disease Progression

Despite immunoglobulin replacement therapy (mean serum IgG 7.6 g/L), lung function and high‑resolution CT (HRCT) scores continue to deteriorate over 4 years ^[198]^B2b. A mean IgG <5 g/L during follow‑up was associated with worsening of linear and irregular opacities on HRCT ^[198]^B2b. Bronchiectasis develops in 27 % of patients and is more frequent with longer diagnostic delay ^[92]^B2b. In granulomatous‑lymphocytic (GL‑ILD), high‑dose corticosteroid induction (≥0.3 mg/kg ) improved HRCT and forced vital capacity, achieving long‑term remission in 42 % of patients; low‑dose maintenance provided no benefit and relapse response was poor ^[139]^C4.

Other Outcomes

Pregnancies in women with CVID result in live births 77 % of the time, but risks of , vaginal bleeding, preeclampsia, , and low birth weight are significantly increased compared with the general population ^[200]^B2b. Rarely, AA amyloidosis complicates CVID after a mean delay of 16 years from PID diagnosis; bronchiectasis is a warning sign, and 50 % of affected patients died ^[205]^C4.

Pearl: In CVID, survival is predicted less by infection frequency than by the development of noninfectious complications, hepatopathy, severe enteropathy, and lymphopenia define a subgroup with premature mortality before age 70 and should trigger intensified surveillance and consideration of advanced therapies ^[16]^B3b^[88]^B2b.

Special Populations and Pregnancy

▸Pediatric CVID has high morbidity and mortality; switched memory B cells <5/mL identify highest-risk children.
▸Pregnancy in CVID is high-risk (preterm labour, preeclampsia, stillbirth) but fertility is normal; IVIG is safe and breastfeeding is protective.
▸Elderly patients present with more non-infectious features; comorbidities demand individualized immunoglobulin dosing and infection surveillance.

Dx Diagnostic Essentials: In children with recurrent sinopulmonary infections, failure to thrive, or autoimmune cytopenias, check immunoglobulin levels and switched memory B cells, CVID is often missed until irreversible lung damage occurs.

Prognosis in CVID varies by age at presentation and by the physiologic demands of pregnancy, aging, and immune compromise. These special populations require tailored diagnostic thresholds and modified strategies.

Pediatrics

In children, recurrent sinopulmonary infections are the most common presentation, but failure to thrive, autoimmune cytopenias, bronchiectasis, and growth hormone deficiency are seen ^[21]^C4. Diagnostic delay averages 8.9 years from symptom onset, and the clinical signature, frequency of common infections and antibiotic prescriptions, can be detected by machine learning up to 10 years before formal diagnosis ^[215]^B3b^[223]^B2b. Patients with <5 switched memory B cells/mL (Group I) are at higher risk for meningitis, sepsis, bronchiectasis, granulomatous lung disease, autoimmune cytopenias, and hematologic malignancies ^[77]^B2b. Severe fatigue affects nearly 20% of pediatric patients and is not related to disease activity ^[219]^B2c. Subcutaneous immunoglobulin (SCIG) is well tolerated even in children with comorbid bleeding disorders, enabling home therapy ^[159]^C4. Mortality is increased in pediatric-onset CVID, with death most often from infection, and lung disease (OR 5) and severe/opportunistic infection (OR 9) directly associated with mortality ^[171]^B2b. Early diagnosis and regular surveillance for noninfectious complications are paramount.

Pregnancy

Fertility in women with CVID is not decreased, but pregnancies carry significantly higher risks. In a cohort of 54 women with 115 pregnancies, complications included threat of preterm labour (p<0.0001), vaginal bleeding (p=0.0001), eclampsia/preeclampsia (p=0.009), and (p<0.0001) compared with the general population; low birth weight (<2500 g) was also more frequent (p<0.0001) ^[200]^B2b. The number of unsuccessful pregnancies was higher in symptomatic untreated women ^[200]^B2b.

Immunoglobulin replacement therapy (IgRT) should be continued throughout pregnancy. Intravenous immunoglobulin (IVIG), dosed to maintain trough IgG >500-700 mg/dL, is safe and has no moderate or severe adverse effects in pregnancy ^[200]^B2b. Cord/maternal blood ratios of total IgG and specific antibodies show good placental transfer ^[135]^C4. is encouraged: colostrum from CVID mothers contains protective antibodies that inhibit enteropathogenic E. coli adhesion, providing local protection for the infant ^[135]^C4. IgA deficiency was found in 23% of children born to CVID mothers, warranting follow-up ^[200]^B2b. A multidisciplinary team including maternal-fetal medicine, immunology, and neonatology is essential ^[137]^D5.

Elderly

CVID diagnosed after age 50 often presents with bronchitis, arthritis, depression, and fatigue rather than classic infection patterns ^[220]^B2b. Chronic lung disease, which increases with age, is a major risk factor for hospitalization (p=0.0008) ^[194]^C4. Comorbidities such as diabetes, , and renal impairment complicate management. IgG trough targets should be individualized, balancing infection prevention against volume overload risk. Subcutaneous immunoglobulin may be preferred to avoid hemodynamic stress of IVIG in frail patients. Elderly patients have higher rates of lymphoma than younger cohorts, though not always statistically significant ^[220]^B2b.

Immunocompromised Settings

Patients with CVID who require additional immunosuppression (e.g., for autoimmune complications or post-transplant) face compounded infection risk. SARS-CoV-2 infection can elicit robust T-cell responses even without antibody production in some CVID patients ^[221]^B3b. Mortality from in CVID is highest in those aged 50-60, dramatically exceeding general population rates (14.3% vs 0.6%) ^[194]^C4. Persistent vaccine-derived poliovirus infection, although rare, has been reported in CVID and may require novel antivirals such as remdesivir ^[177]^C4. Any addition of immunosuppressive therapy demands intensified surveillance and antimicrobial prophylaxis.

Pearl: Elderly patients present with more non-infectious features; comorbidities demand individualized immunoglobulin dosing and infection surveillance.

Prevention, Screening & Surveillance

▸Newborn SCID screening (TREC) may detect IKZF1-related CVID, though CVID is typically late-onset; cascade genetic screening of at-risk relatives can identify monogenic causes in 27% of families.
▸Established CVID warrants systematic surveillance for lymphoma (10-fold excess risk), gastric cancer (34% intestinal metaplasia on screening endoscopy), and lung disease (bronchiectasis/GLILD).
▸Influenza and mRNA COVID-19 vaccines are safe and recommended; humoral responses are often impaired but T-cell responses are preserved in half of patients, and additional vaccine doses may be needed.

HY High Yield: In CVID, gastric premalignant lesions are rarely visible endoscopically; standardized biopsy protocols (antrum, body, fundus, any focal lesions) are essential for screening [95].

From pregnancy through adulthood, prevention of infections and early detection of complications rely on proactive screening and tailored vaccination. Although CVID cannot be prevented, its sequelae, bronchiectasis, lymphoma, gastric cancer, and autoimmune cytopenias, can be mitigated by systematic surveillance and timely intervention.

Prevention through Early Diagnosis: Newborn and Family Screening

Newborn screening for severe combined immunodeficiency (SCID) using T-cell receptor excision circles (TREC) can incidentally identify infants destined to develop CVID. Heterozygous IKZF1 mutations, a monogenic cause of CVID, can produce low TREC values and profound B-cell deficiency at birth, though spontaneous T-cell recovery may occur ^[206]^C4. Current newborn screening programs now define the true incidence of SCID and enable early treatment ^[10]^D5; however, CVID typically presents later, so a normal TREC does not rule out future disease. Family members of CVID patients frequently harbor immune aberrancies, 32-62% report symptoms suggestive of primary immunodeficiency, and B-cell subsets can be 5- to 10-fold reduced in unaffected relatives ^[84]^C4. Targeted next-generation sequencing panels (e.g., for TNFRSF13B, ICOS, NFKB2) identify monogenic causes in 27% of tested CVID patients, enabling cascade screening ^[232]^C4.

Screening for Established Complications

Gastric cancer and lymphoma: In CVID, the prevalence of malignancy reaches 20.4%, with non-Hodgkin lymphoma (predominantly ) as the most common type ^[97]^C4. The USIDNET registry reports a 10-fold excess of lymphoma in men and 8.34-fold in women ^[229]^B2c. risk is also elevated (standardized incidence ratio 6.55) ^[108]^B3b. Routine screening gastroscopy with standardized biopsies is recommended: 34% of CVID patients harbor intestinal metaplasia or atrophic gastritis, which is rarely predicted macroscopically ^[95]^B3b. Proposed protocols include baseline endoscopy at diagnosis and repeat every 3-5 years, especially in smokers or those with Helicobacter pylori infection.

Lung disease: Bronchiectasis and (GLILD) are common and worsen survival ^[56]^D5. Regular and low-threshold high-resolution CT are advised.

Autoimmune thrombocytopenia: Maintaining IgG trough levels above 7 g/L is associated with fewer AITP episodes, regardless of subcutaneous or intravenous immunoglobulin route ^[234]^B2b.

Vaccine-Related Prevention

Influenza vaccination is recommended annually; despite impaired humoral responses, most CVID patients mount measurable T-cell responses to the vaccine ^[55]^B2b. mRNA vaccines are safe and immunogenic in most patients, humoral responses develop in 52-83% but wane rapidly, while T-cell responses persist in one-third to one-half of patients ^[59]^B2b^[65]^B2b^[72]^C4. Neutralizing antibody titers are lower than in healthy controls, and additional doses are often needed ^[72]^C4. CMV latency may reduce T-cell responsiveness to COVID-19 vaccination ^[235]^B2c. Live vaccines are contraindicated. Pneumococcal polysaccharide vaccine (PPSV23) remains a useful tool for functional antibody assessment, even after conjugate vaccine exposure ^[166]^D5. Patient education should emphasize realistic expectations: vaccines may not prevent infection but can reduce severe disease.

Population Screening for Antibody Deficiency

In resource-limited settings, calculated globulin (CG) <22 g/L (sensitivity 80%, specificity 87%) and gammaglobulin <8.9 g/L (sensitivity 96%, specificity 88%) on serum protein electrophoresis can identify hypogammaglobulinemia ^[227]^C4. The Rapid IgG Screen (RIgGS) point-of-care test differentiates low from normal IgG, aiding polio surveillance and early diagnosis ^[231]^C4.

Pearl: Influenza and mRNA COVID-19 vaccines are safe and recommended; humoral responses are often impaired but T-cell responses are preserved in half of patients, and additional vaccine doses may be needed.

Screening and Prevention Strategies in CVID

Target	Screening Tool	Recommendation	Source
Gastric cancer / lymphoma	Upper endoscopy with standardized biopsies	Baseline at diagnosis; repeat every 3-5 years	van der Poorten 2018 ^[95]^B3b
Lymphoma	Clinical vigilance, low-threshold imaging	Annual history, exam; CT if symptoms	USIDNET 2017 ^[229]^B2c
Lung disease (bronchiectasis/GLILD)	PFTs, HRCT	Baseline PFTs; HRCT if clinical suspicion	Schussler 2016 ^[56]^D5
Autoimmune thrombocytopenia	Serum IgG trough	Maintain >7 g/L	Camacho-Ordonez 2025 ^[234]^B2b
Antibody deficiency (family members)	Targeted NGS panel	Offer to relatives with symptoms or low immunoglobulins	Kermode 2022 ^[232]^C4
Hypogammaglobulinemia (population)	CG or gammaglobulin electrophoresis	CG <22 g/L or gammaglobulins <8.9 g/L	Mokrane 2026 ^[227]^C4

References

[1]
Unger S, Seidl M, van Schouwenburg P et al.. “The TH1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency.” The Journal of allergy and clinical immunology (2017). PMID: 28554560 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Hypersensitivity Mechanism Type
[2]
Jamee M, Zaki-Dizaji M, Lo B et al.. “Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32428713 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Prognosis & Natural History
[3]
DiGiacomo DV, Roelstraete B, Lebwohl B et al.. “Predominantly antibody deficiency and the association with celiac disease in Sweden: A nationwide case-control study.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 38331244 ↗
L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
[4]
Kaplan B, Kopyltsova Y, Khokhar A et al.. “Rituximab and immune deficiency: case series and review of the literature.” The journal of allergy and clinical immunology. In practice (2014). PMID: 25213054 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[5]
Fedor ME, Rubinstein A. “Effects of long-term low-dose corticosteroid therapy on humoral immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16892792 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway
[6]
Schwab C, Gabrysch A, Olbrich P et al.. “Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.” The Journal of allergy and clinical immunology (2018). PMID: 29729943 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
[7]
Magerus A, Rensing-Ehl A, Rao VK et al.. “Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): A proposed approach to redefining ALPS and other lymphoproliferative immune disorders.” The Journal of allergy and clinical immunology (2023). PMID: 37977527 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[8]
Lorenzini T, Fliegauf M, Klammer N et al.. “Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.” The Journal of allergy and clinical immunology (2020). PMID: 32278790 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[9]
Jørgensen SF, Braadland PR, Ueland T et al.. “Tryptophan-kynurenine metabolites associate with inflammation and immunologic phenotypes in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 40378971 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks
[10]
Chinen J, Notarangelo LD, Shearer WT. “Advances in basic and clinical immunology in 2014.” The Journal of allergy and clinical immunology (2015). PMID: 25956014 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History, Prevention, Screening & Surveillance
[11]
Tuijnenburg P, Lango Allen H, Burns SO et al.. “Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.” The Journal of allergy and clinical immunology (2018). PMID: 29477724 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[12]
Friedmann D, Payne KJ, Cousin V et al.. “Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41314478 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
[13]
Agondi RC, Barros MT, Rizzo LV et al.. “Allergic asthma in patients with common variable immunodeficiency.” Allergy (2009). PMID: 19839975 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[14]
DiGiacomo DV, Roelstraete B, Hammarström L et al.. “Predominant Antibody Deficiency and Risk of Microscopic Colitis: a Nationwide Case-Control Study in Sweden.” Journal of clinical immunology (2023). PMID: 37162615 ↗
L3CASE_CONTROLCited in: Definition, Classification & Hypersensitivity Mechanism Type
[15]
Seidel MG, Kindle G, Gathmann B et al.. “The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.” The journal of allergy and clinical immunology. In practice (2019). PMID: 30776527 ↗
L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[16]
Bez P, Smits B, Geier C et al.. “Uncovering Risk Factors of Premature Mortality in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40090481 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[17]
Ameratunga R, Edwards ESJ, Lehnert K et al.. “The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like Disorders.” The journal of allergy and clinical immunology. In practice (2023). PMID: 36796510 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[18]
Filion CA, Taylor-Black S, Maglione PJ et al.. “Differentiation of Common Variable Immunodeficiency From IgG Deficiency.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30557717 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
[19]
Elmoursi A, DiGiacomo DV, Farmer JR et al.. “Hepatic Manifestations in Common Variable Immunodeficiency Associated With Mortality and Worse Hospital Outcomes in Nationwide Analysis Using National Readmission Database.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40998257 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
[20]
Agress A, Oprea Y, Roy S et al.. “The Association Between Malignancy, Immunodeficiency, and Atopy in IgE-Deficient Patients.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37863316 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors
[21]
Ogershok PR, Hogan MB, Welch JE et al.. “Spectrum of illness in pediatric common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 17165275 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Special Populations & Pregnancy
[22]
Ariue B, Patel NC, Bellanti JA. “Lessons from the American College of Allergy, Asthma and Immunology inborn errors of immunity survey: Advancing diagnostic and therapeutic strategies for the practicing allergist-immunologist.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41057108 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[23]
Lee WI, Huang JL, Kuo ML et al.. “Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18051214 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type
[24]
Ombrello MJ, Remmers EF, Sun G et al.. “Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.” The New England journal of medicine (2012). PMID: 22236196 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[25]
Park MA, Li JT, Hagan JB et al.. “Common variable immunodeficiency: a new look at an old disease.” Lancet (London, England) (2008). PMID: 18692715 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[26]
Urban B, Batlle-Masó L, Perurena-Prieto J et al.. “Heterozygous Predicted Loss-of-function Variants of TRAF3 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 39579173 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[27]
Drabe CH, Laustsen MM, Marquart HV et al.. “Genetics in a Danish Common Variable Immunodeficiency Cohort.” Journal of clinical immunology (2025). PMID: 40455168 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[28]
Thoré P, Jaïs X, Savale L et al.. “Pulmonary Hypertension in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34110542 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[29]
Bargir UA, Setia P, Desai M et al.. “Common Variable Immunodeficiency Disorder: A Decade of Insights from a Cohort of 150 Patients in India and the Use of Machine Learning Algorithms to Predict Severity.” Journal of clinical immunology (2025). PMID: 40856873 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
[30]
Thouvenel CD, Tipton CM, Yamazaki Y et al.. “Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.” Journal of clinical immunology (2025). PMID: 39812873 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[31]
van Stigt AC, von der Thüsen JH, Mustafa DAM et al.. “Granulomas in Common Variable Immunodeficiency Display Different Histopathological Features Compared to Other Granulomatous Diseases.” Journal of clinical immunology (2024). PMID: 39373788 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[32]
Fortier JC, Haltigan E, Cavero-Chavez V et al.. “Clinical and Phenotypic Characterization of Common Variable Immunodeficiency Diagnosed in Younger and Older Adults.” Journal of clinical immunology (2022). PMID: 35588029 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[33]
Hägele P, Staus P, Scheible R et al.. “Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.” The Lancet. Haematology (2024). PMID: 38302222 ↗
L2COHORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification
[34]
Llobet MP, Soler-Palacin P, Detkova D et al.. “Common variable immunodeficiency: 20-yr experience at a single centre.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2008). PMID: 18798799 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Prevention, Screening & Surveillance
[35]
Perez-Perez D, Santos-Argumedo L, Rodriguez-Alba JC et al.. “Analysis of LRBA pathogenic variants and the association with functional protein domains and clinical presentation.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 38923448 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[36]
Costagliola G, De Marco E, Amato L et al.. “Sponge-like sonographic pattern of the spleen in immune dysregulation disorders.” Frontiers in immunology (2026). PMID: 42375368 ↗
L3CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[37]
Endo Y, Koga T, Kurushima S et al.. “Case Report: Novel IRF2BP2 variant in a Japanese patient with impaired B-cell differentiation, Th1 polarization, and systemic immune dysregulation.” Frontiers in immunology (2025). PMID: 41246352 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation
[38]
Sormani J, Belot A, Nove-Josserand R et al.. “A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency.” Journal of clinical immunology (2025). PMID: 41219619 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[39]
Nishikawa T, Tomomasa D, Hijikata A et al.. “Case Report: CD40LG Arg203Ile variant underlies atypical phenotype of X-linked hyper IgM syndrome.” Frontiers in immunology (2025). PMID: 40391217 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[40]
González-Torbay A, Reche-Yebra K, Clemente-Bernal Á et al.. “Functional insights of an uncommon hypomorphic variant in IL2RG as a monogenic cause of CVID-like disease with antibody deficiency and T CD4 lymphopenia.” Frontiers in immunology (2025). PMID: 40170851 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
[41]
Ak B, Parıltay E, Gümüşburun R et al.. “Uniparental Disomy of Chromosome 4: A Case of Whole Chromosome UPD Presenting with LRBA Deficiency.” Journal of clinical immunology (2024). PMID: 39289195 ↗
L4CASE_REPORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism
[42]
Le Coz C, Bengsch B, Khanna C et al.. “Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.” The Journal of allergy and clinical immunology (2019). PMID: 31445098 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[43]
von Spee-Mayer C, Echternach C, Agarwal P et al.. “Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33223097 ↗
L2TRIAL_NONRANDOMCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
[44]
Lang A, Agharahimi A, Vogel TP et al.. “From CVID to PIRD: Genetic Testing Leading to Signal Transducer and Activator of Transcription 3 Gain-of-Function Diagnosis and Directed Therapy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41999916 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[45]
Agarwal S, Cunningham-Rundles C. “Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304889 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[46]
Narula S, LaRosa DF, Kamoun M et al.. “Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17521034 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation
[47]
Udemgba C, Pillay B, Shafer S et al.. “IRF2BP2 deficiency: An important form of common variable immunodeficiency with inflammation.” The Journal of allergy and clinical immunology (2025). PMID: 40090425 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[48]
Chinen J, Cowan MJ. “Advances and highlights in primary immunodeficiencies in 2017.” The Journal of allergy and clinical immunology (2018). PMID: 30170128 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[49]
Abyazi ML, Bell KA, Gyimesi G et al.. “Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications.” The Journal of allergy and clinical immunology (2021). PMID: 34146579 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[50]
Kaarbø M, Yang M, Hov JR et al.. “Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses.” The Journal of allergy and clinical immunology (2022). PMID: 36220400 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism
[51]
Le Coz C, Trofa M, Butler DL et al.. “The common variable immunodeficiency IgM repertoire narrowly recognizes erythrocyte and platelet glycans.” The Journal of allergy and clinical immunology (2024). PMID: 38692308 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[52]
Ho HE, Radigan L, Qi J et al.. “Bruton tyrosine kinase modulates systemic immune activation to bacterial translocation in primary antibody deficiencies.” The Journal of allergy and clinical immunology (2025). PMID: 41033468 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism
[53]
Boast B, Goel S, González-Granado LI et al.. “TCF3 haploinsufficiency defined by immune, clinical, gene-dosage, and murine studies.” The Journal of allergy and clinical immunology (2023). PMID: 37277074 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[54]
Urdea D, Mereuta DV, Iorga RE et al.. “Concurrent hereditary angioedema type I and common variable immunodeficiency presenting as suspected antibiotic hypersensitivity: Case report and literature discussion.” The World Allergy Organization journal (2026). PMID: 42221876 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[55]
Friedmann D, Goldacker S, Peter HH et al.. “Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32330665 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[56]
Schussler E, Beasley MB, Maglione PJ. “Lung Disease in Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27836055 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[57]
Yin J, Hayes KM, Ong MS et al.. “Common Variable Immunodeficiency Clinical Manifestations Are Shaped by Presence and Type of Heterozygous NFKB1 Variants.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39672378 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[58]
Ameratunga R, Longhurst H, Steele R et al.. “Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.” The journal of allergy and clinical immunology. In practice (2021). PMID: 34182162 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[59]
Milota T, Smetanova J, Skotnicova A et al.. “Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36379409 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[60]
van de Ven A, Mader I, Wolff D et al.. “Structural Noninfectious Manifestations of the Central Nervous System in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31857261 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[61]
Agarwal S, Cunningham-Rundles C. “Autoimmunity in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2019). PMID: 31349011 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[62]
Durkee-Shock JR, Keller MD. “Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35718282 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prevention, Screening & Surveillance
[63]
Ballow M. “Managing comorbid complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2013). PMID: 24267402 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks
[64]
Maglione PJ, Overbey JR, Radigan L et al.. “Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 24880814 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[65]
Rosenthal JA, Papa MP, Sanz M et al.. “Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 36736722 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[66]
Hashiguchi S, Tomomasa D, Nishikawa T et al.. “18q Deletion Syndrome Presenting with Late-Onset Combined Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38896123 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism
[67]
Vossen MG, Kartnig F, Mrak D et al.. “Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.” Wiener klinische Wochenschrift (2024). PMID: 39446203 ↗
L2RCTCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway
[68]
Yel L. “Selective IgA deficiency.” Journal of clinical immunology (2010). PMID: 20101521 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway
[69]
Cunningham-Rundles C. “Autoimmune manifestations in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18322785 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[70]
Strohmeier V, Andrieux G, Unger S et al.. “Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection.” Journal of clinical immunology (2022). PMID: 36282455 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[71]
Sekinaka Y, Mitsuiki N, Imai K et al.. “Common Variable Immunodeficiency Caused by FANC Mutations.” Journal of clinical immunology (2017). PMID: 28493158 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[72]
Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R et al.. “Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.” Journal of clinical immunology (2021). PMID: 34787773 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[73]
Rodríguez-Cortez VC, Del Pino-Molina L, Rodríguez-Ubreva J et al.. “Dissecting Epigenetic Dysregulation of Primary Antibody Deficiencies.” Journal of clinical immunology (2016). PMID: 26984849 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[74]
Hel Z, Huijbregts RP, Xu J et al.. “Altered serum cytokine signature in common variable immunodeficiency.” Journal of clinical immunology (2014). PMID: 25246148 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism
[75]
Yang M, Kaarbø M, Myhre V et al.. “Altered Genome-Wide DNA Methylation in the Duodenum of Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2024). PMID: 38780872 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism
[76]
Soltani M, Rezaei M, Fekrvand S et al.. “Role of rare immune cells in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 34937129 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[77]
Yong PL, Orange JS, Sullivan KE. “Pediatric common variable immunodeficiency: immunologic and phenotypic associations with switched memory B cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2010). PMID: 20337966 ↗
L2OTHERCited in: Pathophysiology & Immune Mechanism, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[78]
Lenti MV, Savioli J, Achilli G et al.. “Autoimmune diseases associated with common variable immune deficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 33236426 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks
[79]
Kutukculer N, Gulez N. “The outcome of patients with unclassified hypogammaglobulinemia in early childhood.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19196447 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[80]
Tegtmeyer D, Seidl M, Gerner P et al.. “Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017). PMID: 28513998 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[81]
Zeng W, Feng X, Liang B et al.. “Good syndrome presenting with multiple pulmonary infections: a case report involving metagenomic sequencing diagnosis.” Frontiers in medicine (2025). PMID: 40904363 ↗
L4CASE_REPORTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[82]
Consolini R, Maestrini G, Abu-Rumeileh S et al.. “The Intertwining Between Arthritis and Inborn Errors of Immunity.” Journal of clinical medicine (2026). PMID: 42123030 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism
[83]
Yang M, Kaarbø M, Myhre V et al.. “Distinct Proteomic and Transcriptomic Profiles in T-cells and Monocytes in Patients with Common Variable Immunodeficiency: an Exploratory Study.” Journal of clinical immunology (2026). PMID: 41991796 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[84]
Comans SET, Sprenkeler EGG, Koenen MH et al.. “Familial patterns of immune dysregulation in CVID: insights from B- and T-cell phenotyping and antibody profiling.” Frontiers in immunology (2026). PMID: 41909677 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Prevention, Screening & Surveillance
[85]
Briassouli E, Marinakis N, Spoulou V et al.. “IL2RG-related immunodeficiencies: from SCID to atypical presentations.” Frontiers in immunology (2026). PMID: 41909668 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History
[86]
Fekrvand S, Abolhassani H, Esfahani ZH et al.. “Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.” Journal of clinical immunology (2024). PMID: 39466473 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[87]
Egg D, Rump IC, Mitsuiki N et al.. “Therapeutic options for CTLA-4 insufficiency.” The Journal of allergy and clinical immunology (2021). PMID: 34111452 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[88]
Torres-Valle A, Neirinck J, Silva SL et al.. “Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2025). PMID: 41176068 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[89]
Gray PE, David C. “Inborn Errors of Immunity and Autoimmune Disease.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37119983 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[90]
Jolles S. “The variable in common variable immunodeficiency: a disease of complex phenotypes.” The journal of allergy and clinical immunology. In practice (2013). PMID: 24565700 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks
[91]
Cunningham-Rundles C. “Current concepts: Common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41274495 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[92]
Moazzami B, Mohayeji Nasrabadi MA, Abolhassani H et al.. “Comprehensive assessment of respiratory complications in patients with common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32007567 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[93]
Ferastraoaru D, Gross R, Rosenstreich D. “Increased malignancy incidence in IgE deficient patients not due to concomitant Common Variable Immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28778662 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[94]
De Renzis C, Gambier RF, Gigante A et al.. “Chronic Kidney Disease in Common Variable Immunodeficiency: a Multicenter Study.” Journal of clinical immunology (2025). PMID: 40407942 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[95]
van der Poorten DK, McLeod D, Ahlenstiel G et al.. “Gastric Cancer Screening in Common Variable Immunodeficiency.” Journal of clinical immunology (2018). PMID: 30219982 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
[96]
Garcia-Prat M, Batlle-Masó L, Parra-Martínez A et al.. “Role of Skewed X-Chromosome Inactivation in Common Variable Immunodeficiency.” Journal of clinical immunology (2024). PMID: 38265673 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[97]
Gumusburun R, Yıldırım O, Karakoc M et al.. “Malignancy in Adults with Inborn Errors of Immunity: A Retrospective Single-Center Study.” Journal of clinical immunology (2025). PMID: 40993321 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[98]
Punj M, Neshat SS, Mateus AYL et al.. “Assessment of Sleep Disorders in Patients with CVID.” Journal of clinical immunology (2024). PMID: 38676767 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[99]
Sperlich JM, Grimbacher B, Soetedjo V et al.. “Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders.” Journal of clinical immunology (2022). PMID: 35015197 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks
[100]
Villa A, Milito C, Deiana CM et al.. “High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.” Journal of clinical immunology (2024). PMID: 38319477 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[101]
Puzenat DT, Cheminant M, Dannaoui E et al.. “Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).” The Journal of infectious diseases (2026). PMID: 42378670 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[102]
Miranda-Bautista J, Martínez-Lozano H, Di Natale M et al.. “The Prognostic Impact of Enteropathy and Liver Disease in Common Variable Immunodeficiency: A Retrospective Cohort Study.” Clinical and translational gastroenterology (2026). PMID: 41324469 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[103]
Dogru D, Dogru Y, Atschekzei F et al.. “Reappraisal of IgG subclass deficiencies: a retrospective comparative cohort study.” Frontiers in immunology (2025). PMID: 40313941 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors
[104]
Cekic S, Metin A, Aytekin C et al.. “The evaluation of malignancies in Turkish primary immunodeficiency patients; a multicenter study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32060950 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[105]
Baris S, Ozen A, Ercan H et al.. “Osteoporosis: an ignored complication of CVID.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 21645119 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification
[106]
Azizi G, Tavakol M, Yazdani R et al.. “Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33774840 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[107]
Zhang J, Cai H, Zhu T et al.. “Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.” Clinical and experimental immunology (2026). PMID: 42252100 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks
[108]
Wenger TA, Collet C, West J et al.. “Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2026). PMID: 42171009 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[109]
Martinez T, Grand Z, Garcia S et al.. “A global perspective on autoimmunity and immunodeficiency: exploring geoepidemiology trends.” Current opinion in immunology (2026). PMID: 41980333 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[110]
Romberg N, Le Coz C, Glauzy S et al.. “Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses.” The Journal of allergy and clinical immunology (2018). PMID: 29935219 ↗
L3TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[111]
Bonilla FA, Barlan I, Chapel H et al.. “International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26563668 ↗
L1OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[112]
Mayampurath A, Ajith A, Anderson-Smits C et al.. “Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36108921 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[113]
DeVries AS, Harper J, Murray A et al.. “Vaccine-derived poliomyelitis 12 years after infection in Minnesota.” The New England journal of medicine (2011). PMID: 21675890 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[114]
Lee TK, Gereige JD, Maglione PJ. “State-of-the-art diagnostic evaluation of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33716149 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[115]
Izadi N, Knight V, Strand M et al.. “An enzyme-linked immunospot assay to evaluate Pneumovax response when on intravenous immunoglobulin.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 34391898 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[116]
Hartono S, Motosue MS, Khan S et al.. “Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28254202 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[117]
Kuehn HS, Boisson B, Cunningham-Rundles C et al.. “Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.” The New England journal of medicine (2016). PMID: 26981933 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance
[118]
Touw CM, van de Ven AA, de Jong PA et al.. “Detection of pulmonary complications in common variable immunodeficiency.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19912551 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[119]
Reznik EV, Iarovoi MD, Romanova TS et al.. “Prolonged Infections and Inflammatory Diseases in Common Variable Immune Deficiency as a Cause of AA Amyloidosis.” Journal of clinical medicine (2026). PMID: 42278892 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[120]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[121]
Varenne F, Siegfried-Vergnon A, Lhomme S et al.. “JC Virus-Related Retinopathy.” JAMA ophthalmology (2025). PMID: 40674067 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, Prognosis & Natural History
[122]
Schwitzguébel AJ, Jandus P, Lacroix JS et al.. “Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis.” The Journal of allergy and clinical immunology (2015). PMID: 26329513 ↗
L1SR_OBSCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[123]
Jerschow E, De Vos GS, Hudes G et al.. “A case of common variable immunodeficiency syndrome associated with Takayasu arteritis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17304891 ↗
L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[124]
Renz H. “Advances in in vitro diagnostics in allergy, asthma, and immunology in 2012.” The Journal of allergy and clinical immunology (2013). PMID: 24139605 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
[125]
Sperlich JM, Grimbacher B, Workman S et al.. “Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28734862 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[126]
Hurst JR, Verma N, Lowe D et al.. “British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28351785 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
[127]
Maglione PJ, Ko HM, Tokuyama M et al.. “Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31430592 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prognosis & Natural History
[128]
Maglione PJ, Overbey JR, Cunningham-Rundles C. “Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.” The journal of allergy and clinical immunology. In practice (2015). PMID: 26372540 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[129]
Roa-Bautista A, Brown LK, Tadros S et al.. “Clinical Features, Immunological Characteristics, and Treatment Outcomes of Campylobacter spp. Infections in Patients With Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37406804 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History
[130]
Busse PJ, Farzan S, Cunningham-Rundles C. “Pulmonary complications of common variable immunodeficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17225714 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[131]
Deyà-Martínez A, Esteve-Solé A, Vélez-Tirado N et al.. “Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2018). PMID: 29532571 ↗
L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[132]
Lopes-da-Silva S, Rizzo LV. “Autoimmunity in common variable immunodeficiency.” Journal of clinical immunology (2008). PMID: 18443901 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History, Prevention, Screening & Surveillance
[133]
Shapiro RS, Wasserman RL, Bonagura V et al.. “Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.” Journal of clinical immunology (2014). PMID: 24477950 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[134]
Hoernes M, Seger R, Reichenbach J. “Modern management of primary B-cell immunodeficiencies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 22122788 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[135]
Palmeira P, Costa-Carvalho BT, Arslanian C et al.. “Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19220771 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[136]
Stojanovic M, Stojkovic-Lalosevic M, Stankovic S et al.. “Non-invasive assessment of hepatic involvement in common variable immunodeficiency and agammaglobulinemia using enhanced liver fibrosis score and shearwave elastography.” Frontiers in immunology (2026). PMID: 42421971 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup
[137]
Elmoursi A, Charlier C, Cunningham-Rundles C et al.. “Insights into Clinical Challenges and Management of Primary and Secondary Antibody Deficiency in Pregnancy.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42250902 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[138]
Matson EM, Ware MS, Feng F et al.. “Coexistent alterations of BAFF and B-cell phenotypes in complicated CVID course.” The Journal of allergy and clinical immunology (2026). PMID: 42219089 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[139]
Smits B, Goldacker S, Seneviratne S et al.. “The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease.” The Journal of allergy and clinical immunology (2022). PMID: 36587851 ↗
L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[140]
Gardulf A, Abolhassani H, Gustafson R et al.. “Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2018). PMID: 29678747 ↗
L4TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[141]
Chase NM, Verbsky JW, Hintermeyer MK et al.. “Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).” Journal of clinical immunology (2012). PMID: 22930256 ↗
L4RCTCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[142]
Bergman P, Wullimann D, Gao Y et al.. “Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2022). PMID: 35290571 ↗
L2TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification
[143]
Mandola AB, Sharfe N, Nagdi Z et al.. “Combined immunodeficiency caused by a novel homozygous NFKB1 mutation.” The Journal of allergy and clinical immunology (2020). PMID: 32980423 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[144]
Abraham RS, Marshall JM, Kuehn HS et al.. “Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant.” The Journal of allergy and clinical immunology (2020). PMID: 33007327 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History
[145]
Materne E, Zhou B, DiGiacomo D et al.. “Renal complications in patients with predominantly antibody deficiency in the United States Immune Deficiency Network (USIDNET).” The Journal of allergy and clinical immunology (2024). PMID: 38555979 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification
[146]
Hennig C, Ilginus C, Boztug K et al.. “High-content cytometry and transcriptomic biomarker profiling of human B-cell activation.” The Journal of allergy and clinical immunology (2013). PMID: 24012209 ↗
L5OTHERCited in: Severity, Grading & Risk Stratification
[147]
Bintalib HM, van de Ven AAJM, Rojas-Reyes MX et al.. “Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration.” The European respiratory journal (2026). PMID: 42350065 ↗
L1GUIDELINECited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[148]
Smits BM, Boland SL, Hol ME et al.. “Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38182096 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification
[149]
Yazdani R, Abolhassani H, Kiaee F et al.. “Comparison of Common Monogenic Defects in a Large Predominantly Antibody Deficiency Cohort.” The journal of allergy and clinical immunology. In practice (2018). PMID: 30240888 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[150]
D'Silva SJ, Patrie J, Noonan E et al.. “Undetectable IgE association with noninfectious complications of common variable immune deficiency.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41390140 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks
[151]
Boztug H, Hirschmugl T, Holter W et al.. “NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.” Journal of clinical immunology (2016). PMID: 27338827 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[152]
Slade CA, McLean C, Scerri T et al.. “Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.” Journal of clinical immunology (2019). PMID: 30927119 ↗
L4CASE_REPORTCited in: Severity, Grading & Risk Stratification
[153]
Karafotias I, Martini H, Lee CV et al.. “CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency.” Journal of clinical immunology (2025). PMID: 41288852 ↗
L3OTHERCited in: Severity, Grading & Risk Stratification
[154]
Bergmans B, Fontane Pennock-Janssen L, van Puijenbroek E et al.. “Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin.” Journal of clinical immunology (2025). PMID: 41384995 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History
[155]
Katzenstein TL, Rasmussen LD, Drabe CH et al.. “Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study.” Frontiers in immunology (2022). PMID: 36211430 ↗
L2COHORTCited in: Severity, Grading & Risk Stratification
[156]
Danieli MG, Verga JU, Mezzanotte C et al.. “Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.” Frontiers in immunology (2022). PMID: 35111165 ↗
L4COHORTCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway
[157]
Russo R, Andolfo I, Lasorsa VA et al.. “The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy.” Genes (2021). PMID: 34201032 ↗
L3COHORTCited in: Severity, Grading & Risk Stratification
[158]
van der Heijden J, Geissler J, van Mirre E et al.. “A novel splice variant of FcγRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia.” The Journal of allergy and clinical immunology (2013). PMID: 23545275 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[159]
Arora R, Newton TC, Nelson MR. “Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17941286 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy
[160]
Chinen J, Notarangelo LD, Shearer WT. “Advances in clinical immunology in 2015.” The Journal of allergy and clinical immunology (2016). PMID: 27931534 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[161]
Chinen J, Badran YR, Geha RS et al.. “Advances in basic and clinical immunology in 2016.” The Journal of allergy and clinical immunology (2017). PMID: 28826774 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[162]
Bonilla FA, Geha RS. “2. Update on primary immunodeficiency diseases.” The Journal of allergy and clinical immunology (2006). PMID: 16455342 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[163]
Gathmann B, Mahlaoui N, Gérard L et al.. “Clinical picture and treatment of 2212 patients with common variable immunodeficiency.” The Journal of allergy and clinical immunology (2014). PMID: 24582312 ↗
L2OTHERCited in: Acute Management & Anaphylaxis Pathway
[164]
Wehr C, Gennery AR, Lindemans C et al.. “Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.” The Journal of allergy and clinical immunology (2015). PMID: 25595268 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[165]
Pulvirenti F, Cinetto F, Milito C et al.. “Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32278865 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[166]
Zuzolo J, Zulfiqar MF, Spoelhof B et al.. “Functional testing of humoral immunity in the Prevnar 20 era.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 39681261 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[167]
Lang-Meli J, Fuchs J, Mathé P et al.. “Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 34893946 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[168]
Ilkjær FV, Johansen IS, Martin-Iguacel R et al.. “Evaluating Drug Prescription Patterns in Undiagnosed Common Variable Immunodeficiency Patients.” Journal of clinical immunology (2023). PMID: 37833619 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway
[169]
Ilkjær FV, Rasmussen LD, Martin-Iguacel R et al.. “How to Identify Common Variable Immunodeficiency Patients Earlier: General Practice Patterns.” Journal of clinical immunology (2019). PMID: 31372799 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway
[170]
Lawrence MG, Palacios-Kibler TV, Workman LJ et al.. “Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2018). PMID: 29453744 ↗
L3OTHERCited in: Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance
[171]
Baloh C, Reddy A, Henson M et al.. “30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators.” Journal of clinical immunology (2019). PMID: 31377970 ↗
L2REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[172]
Cagdas D, Halaçlı SO, Tan Ç et al.. “A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.” Journal of clinical immunology (2019). PMID: 31432443 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[173]
Steiner S, Schwarz T, Corman VM et al.. “Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination.” Journal of clinical immunology (2023). PMID: 36932291 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway
[174]
Aiello V, Ferrillo M, Marotta N et al.. “Temporomandibular joint arthritis in rheumatic diseases patients: which are the effective rehabilitative approaches for pain relief? A systematic review.” BMC musculoskeletal disorders (2025). PMID: 39966784 ↗
L1SR_OBSCited in: Acute Management & Anaphylaxis Pathway
[175]
Budhipramono A, Sharma R, Wysocki CA et al.. “Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency.” Journal of clinical apheresis (2024). PMID: 39511768 ↗
L4SR_OBSCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[176]
Napiórkowska-Baran K, Biliński J, Pujanek M et al.. “Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).” Frontiers in cellular and infection microbiology (2024). PMID: 39403201 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway
[177]
Bermingham WH, Canning B, Wilton T et al.. “Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection.” Frontiers in immunology (2023). PMID: 36936936 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[178]
Martins B, Miranda J, Pinto MJ et al.. “Common variable immunodeficiency and its inflammatory neurological manifestations: A case report and literature review.” Multiple sclerosis and related disorders (2022). PMID: 35985210 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[179]
Luterbacher F, Bernard F, Baleydier F et al.. “Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.” Frontiers in immunology (2021). PMID: 35003091 ↗
L4CASE_REPORTCited in: Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy
[180]
Rezaei N, Hedayat M, Aghamohammadi A et al.. “Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.” The Journal of allergy and clinical immunology (2011). PMID: 21514636 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance
[181]
Mazza JM, Lin SY. “Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review.” International forum of allergy & rhinology (2016). PMID: 27187624 ↗
L2SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[182]
Arslan S, Poyraz N, Ucar R et al.. “Magnetic Resonance Imaging May Be a Valuable Radiation-Free Technique for Lung Pathologies in Patients with Primary Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26707785 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[183]
Indinnimeo L, Tancredi G, Barreto M et al.. “Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up.” International journal of immunopathology and pharmacology (2007). PMID: 18179758 ↗
L1RCTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[184]
Pietzsch L, Körholz J, Boschann F et al.. “Hyper-IgE and Carcinoma in CADINS Disease.” Frontiers in immunology (2022). PMID: 35651609 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[185]
Comberiati P, Costagliola G, Carli N et al.. “Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency.” Frontiers in immunology (2019). PMID: 31379880 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[186]
Suyama K, Kawasaki Y, Abe Y et al.. “Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus.” Pediatric nephrology (Berlin, Germany) (2011). PMID: 22207346 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[187]
Zdziarski P, Gamian A. “Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens.” Frontiers in pharmacology (2019). PMID: 30713498 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[188]
Yuan S, Hu X, Zhao Y et al.. “Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.” Frontiers in immunology (2020). PMID: 33240259 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[189]
Antachopoulos C, Walsh TJ, Roilides E. “Fungal infections in primary immunodeficiencies.” European journal of pediatrics (2007). PMID: 17551753 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
[190]
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM et al.. “Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.” The Journal of allergy and clinical immunology (2022). PMID: 35421449 ↗
L2RCTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Complications, Comorbidities & Iatrogenic Risks
[191]
Davé S, Hagan J. “Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18219840 ↗
L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[192]
Morsheimer MM, Rychik J, Forbes L et al.. “Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease.” The journal of allergy and clinical immunology. In practice (2016). PMID: 26897303 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[193]
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH et al.. “Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.” Journal of clinical immunology (2023). PMID: 37231290 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[194]
Giardino G, Milito C, Lougaris V et al.. “The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet).” Journal of clinical immunology (2022). PMID: 35445287 ↗
L4OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[195]
Beyls E, Duthoo E, Backers L et al.. “Investigating Chromosomal Radiosensitivity in Inborn Errors of Immunity: Insights from DNA Repair Disorders and Beyond.” Journal of clinical immunology (2025). PMID: 39945898 ↗
L3OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution
[196]
Lin L, Peng X, Chen L et al.. “Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic.” Pediatric rheumatology online journal (2025). PMID: 40165201 ↗
L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Special Populations & Pregnancy
[197]
Grammatikos A. “Enteropathy in Common Variable Immunodeficiency.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41935739 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks
[198]
Gregersen S, Aaløkken TM, Mynarek G et al.. “Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2010). PMID: 20568383 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History
[199]
Nguyen JT, Green A, Wilson MR et al.. “Neurologic Complications of Common Variable Immunodeficiency.” Journal of clinical immunology (2016). PMID: 27704236 ↗
L4CASE_REPORTCited in: Complications, Comorbidities & Iatrogenic Risks
[200]
Kralickova P, Kurecova B, Andrys C et al.. “Pregnancy Outcome in Patients with Common Variable Immunodeficiency.” Journal of clinical immunology (2015). PMID: 26280892 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History, Special Populations & Pregnancy
[201]
Zarezadeh Mehrabadi A, Aghamohamadi N, Abolhassani H et al.. “Comprehensive Assessment of Skin Disorders in Patients with Common Variable Immunodeficiency (CVID).” Journal of clinical immunology (2022). PMID: 35084691 ↗
L4OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[202]
Elmoursi A, Zhou B, Ong MS et al.. “A Cross-Sectional Study of Health-Related Quality of Life in Patients with Predominantly Antibody Deficiency.” Journal of clinical immunology (2024). PMID: 39110257 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance
[203]
Cinkavuk E, Akyazi N, Calik E et al.. “An ICF framework analysis of the CVID quality of life questionnaire.” Disability and rehabilitation (2026). PMID: 42080371 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[204]
Hayes KM, Boldt K, Schnorr PJ et al.. “Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.” JCI insight (2026). PMID: 41869721 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks
[205]
Delplanque M, Galicier L, Oziol E et al.. “AA Amyloidosis Secondary to Primary Immune Deficiency: About 40 Cases Including 2 New French Cases and a Systematic Literature Review.” The journal of allergy and clinical immunology. In practice (2020). PMID: 33007500 ↗
L4SR_OBSCited in: Prognosis & Natural History
[206]
Kuehn HS, Gloude NJ, Dimmock D et al.. “Abnormal SCID Newborn Screening and Spontaneous Recovery Associated with a Novel Haploinsufficiency IKZF1 Mutation.” Journal of clinical immunology (2021). PMID: 33855675 ↗
L4TRIAL_NONRANDOMCited in: Prognosis & Natural History, Prevention, Screening & Surveillance
[207]
van Leeuwen LPM, Van Coillie S, Prévot J et al.. “Long-term effects of COVID-19 in patients with primary immunodeficiency: An IPOPI worldwide survey.” The Journal of allergy and clinical immunology (2025). PMID: 40316182 ↗
L4OTHERCited in: Prognosis & Natural History
[208]
Verbsky JW, Hintermeyer MK, Simpson PM et al.. “Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.” The Journal of allergy and clinical immunology (2020). PMID: 32745555 ↗
L4OTHERCited in: Prognosis & Natural History
[209]
da Silva SP, Resnick E, Lucas M et al.. “Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events.” Journal of clinical immunology (2011). PMID: 21744182 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[210]
Kuehn HS, Nunes-Santos CJ, Rosenzweig SD. “IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.” Journal of clinical immunology (2021). PMID: 33392855 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[211]
Caka C, Cimen O, Kahyaoğlu P et al.. “Selective IgM deficiency: Follow-up and outcome.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33706406 ↗
L4OTHERCited in: Prognosis & Natural History, Special Populations & Pregnancy
[212]
Navale P, Zimmerman O, Wedner J et al.. “Gastrointestinal pathology in Good's syndrome, thinking beyond common variable immunodeficiency: a clinicopathological observation.” Virchows Archiv : an international journal of pathology (2025). PMID: 40140088 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[213]
Roosens W, Staels F, Van Loo S et al.. “Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study.” Frontiers in immunology (2023). PMID: 37795099 ↗
L4CASE_REPORTCited in: Prognosis & Natural History
[214]
Almejún MB, Campos BC, Patiño V et al.. “Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination.” The Journal of allergy and clinical immunology (2016). PMID: 27713077 ↗
L4OTHERCited in: Special Populations & Pregnancy
[215]
Alsaati N, Penney C, Helbig I et al.. “A predictive model for identification of pediatric individuals with common variable immunodeficiency through electronic medical records.” The Journal of allergy and clinical immunology (2025). PMID: 40058414 ↗
L3OTHERCited in: Special Populations & Pregnancy
[216]
van de Ven AA, Compeer EB, Bloem AC et al.. “Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders.” The Journal of allergy and clinical immunology (2011). PMID: 22130422 ↗
L3OTHERCited in: Special Populations & Pregnancy
[217]
Novice T, Kariminia A, Del Bel KL et al.. “A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.” Journal of clinical immunology (2019). PMID: 31853824 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy
[218]
Freer M, Bhatia R, Preece K et al.. “Dietary intakes and nutritional issues in inborn errors of immunity: a systematic review.” Frontiers in immunology (2024). PMID: 39399505 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[219]
Nijhof LN, van Brussel M, Pots EM et al.. “Severe Fatigue Is Common Among Pediatric Patients with Primary Immunodeficiency and Is Not Related to Disease Activity.” Journal of clinical immunology (2021). PMID: 33728554 ↗
L2OTHERCited in: Special Populations & Pregnancy
[220]
Sanchez LA, Maggadottir SM, Pantell MS et al.. “Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency.” Journal of clinical immunology (2017). PMID: 28755066 ↗
L2OTHERCited in: Special Populations & Pregnancy
[221]
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M et al.. “Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.” Journal of clinical immunology (2021). PMID: 33983545 ↗
L3OTHERCited in: Special Populations & Pregnancy
[222]
Tanyildiz HG, Dincaslan H, Yavuz G et al.. “Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.” Journal of clinical immunology (2016). PMID: 27492260 ↗
L4OTHERCited in: Special Populations & Pregnancy
[223]
Quinti I, Soresina A, Spadaro G et al.. “Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.” Journal of clinical immunology (2007). PMID: 17510807 ↗
L2OTHERCited in: Special Populations & Pregnancy
[224]
Phuong LK, Cheung A, Agrawal R et al.. “Inborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.” The Pediatric infectious disease journal (2023). PMID: 37463351 ↗
L2COHORTCited in: Special Populations & Pregnancy
[225]
Adin-Cinar S, Gelmez MY, Akdeniz N et al.. “Functions of NK and iNKT cells in pediatric and adult CVID, ataxia telangiectasia and agammaglobulinemia patients.” Immunology letters (2021). PMID: 34599947 ↗
L3TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[226]
Grześk E, Kołtan S, Dąbrowska A et al.. “Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.” Frontiers in immunology (2022). PMID: 35990691 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy
[227]
Mokrane L, Tahiat A, Taguemount S et al.. “Improving screening for antibody deficiency using calculated globulin and serum protein electrophoresis.” Frontiers in immunology (2026). PMID: 41929515 ↗
L4OTHERCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance
[228]
Lucas M, Lee M, Lortan J et al.. “Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.” The Journal of allergy and clinical immunology (2010). PMID: 20471071 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[229]
Mayor PC, Eng KH, Singel KL et al.. “Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.” The Journal of allergy and clinical immunology (2017). PMID: 28606585 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[230]
Green PHR, Paski S, Ko CW et al.. “AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.” Gastroenterology (2022). PMID: 36137844 ↗
L1GUIDELINECited in: Prevention, Screening & Surveillance
[231]
Israeli S, Golden A, Atalig M et al.. “A Novel Point-of-Care Rapid Diagnostic Test for Screening Individuals for Antibody Deficiencies.” Journal of clinical immunology (2021). PMID: 34839430 ↗
L4OTHERCited in: Prevention, Screening & Surveillance
[232]
Kermode W, De Santis D, Truong L et al.. “A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield: Results from the Perth CVID Cohort Study.” The Journal of molecular diagnostics : JMD (2022). PMID: 35570134 ↗
L4COHORTCited in: Prevention, Screening & Surveillance
[233]
Nassereddin AT, Zayed Y, King RB et al.. “A 28-Year-Old Woman With Nail Discoloration, Recurrent Bronchitis, and Left-Sided Facial Swelling.” Chest (2023). PMID: 37945195 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[234]
Camacho-Ordonez N, Hirsch A, Campos L et al.. “Do CVID patients on SCIG have more autoimmune (thrombo)cytopenic events than CVID patients on IVIG?” Frontiers in immunology (2025). PMID: 41394859 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[235]
Alba-Cano T, Alonso R, Balastegui-Martín H et al.. “Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients.” Frontiers in immunology (2025). PMID: 41098714 ↗
L2OTHERCited in: Prevention, Screening & Surveillance

Common Variable Immunodeficiency

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Immunodeficiency Defect Type

Clinical Phenotypes

Pathophysiology & Immune Mechanism

B-Cell Defects: The Core Humoral Failure

T-Cell Dysregulation and Follicular Skewing

Microbial Translocation and Innate Immune Activation

Genetic and Epigenetic Contributions

Epidemiology, Etiology & Risk Factors

Genetic Etiologies

Environmental and Immune Triggers

Risk Factors for Associated Conditions

Special Considerations

Clinical Presentation

Presenting Symptoms

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup

Diagnostic Criteria and Gold Standard

Laboratory Studies

Allergy Testing

Genetic Testing

Diagnostic Algorithm

Severity, Grading & Risk Stratification

Clinical Phenotype-Based Stratification

Immunologic Biomarkers for Risk Stratification

Genetic Stratification

Complications-Based Severity Grading

Controversies and Guideline Disagreement

Acute Management & Anaphylaxis Pathway

Step 1: Recognition and Immediate Intervention

Step 2: CVID-Specific Risk Factors and Prevention

Step 3: Management of Infusion Reactions

Step 4: Monitoring and Follow-Up

Step 5: Transition to Long-Term Management

Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics

Step 1: Initial Assessment and Severity Classification

Step 2: First-Line Interventions

Step 3: Second-Line and Biologic Therapy

Step 4: Monitoring and Titration

Step 5: Transition and Long-Term Strategies

Dosing and Evidence Table

Controversies and Guideline Disagreement

Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution

Step 3: Antimicrobial Prophylaxis

Step 4: Immune Reconstitution: HSCT and Gene Therapy

Controversies in Practice

Complications, Comorbidities & Iatrogenic Risks

Immune Dysregulation and Autoimmunity

Respiratory Complications and Monitoring

Gastrointestinal and Hepatic Complications

Malignancy Risk

Hospital-Acquired and Iatrogenic Complications

Prognosis & Natural History

Mortality and Causes of Death

Prognostic Biomarkers

Pulmonary Disease Progression

Other Outcomes

Special Populations and Pregnancy

Pediatrics

Pregnancy

Elderly

Immunocompromised Settings

Prevention, Screening & Surveillance

Prevention through Early Diagnosis: Newborn and Family Screening

Screening for Established Complications

Vaccine-Related Prevention

Population Screening for Antibody Deficiency

References

Step 3: of Infusion Reactions